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Background and Aims:  
Allergic diseases are common and the prevalence has been increasing worldwide over the past 
decades. Knowledge about aetiology, pathogenesis and risk factors are still lacking and 
diagnostic tools are suboptimal. The microbiota of the mucosa and skin is  important for the 
development of the immune system, and Staphylococcus aureus colonization has been linked 
to the development of allergic diseases. Fish is a healthy nutrient and consumption of fish is 
increasing, but fish is also one of the most common food allergens. Cross-sensitization and 
cross-reactivity to multiple fish species are common among fish allergic patients, but some 
patients may be tolerant to one or more species.  
The overall aim of this thesis is to contribute to the understanding of the development of 
multiple allergic diseases and multiple allergies in children and adolescents. My first aim was 
to gain novel insight in the epidemiology of allergic diseases in adolescents in the Arctic 
region of Norway. Moreover, I aimed to investigate how allergic diseases and multiple 
allergen sensitizations are associated with S. aureus carriage and enterotoxin-sensitization. 
My second aim was to contribute to novel insight in cross-reactivity between fish species in 
fish allergic children and adolescents sensitized to multiple fish species. Finally, I aimed to 
study the utility of existing and novel specific IgE (sIgE) tests in the diagnostic work-up of 
fish allergy, and to estimate threshold doses for allergic reactions to different fish species. 
Material and Methods: 
Prevalence`s of allergic diseases and associations to S. aureus were studied in a cross-
sectional study including 868 third year high-school students in the municipalities of Tromsø 
and Balsfjord using a standardized questionnaire, clinical examinations, measurements of 
sIgE to multiple food and inhalant allergens, nasal S. aureus carriage and sensitization to 
staphylococcal enterotoxins (Tromsø Study Fit Futures 2). Cross-reactivity in fish allergy was 
studied in a clinical trial with double-blind, placebo-controlled food challenges with cod, 
salmon and mackerel, a questionnaire and measurement of sIgE to traditional allergen extracts 







In the “Tromsø Study Fit Futures 2”, the prevalence of current asthma, atopic dermatitis and 
allergic rhinitis were 11.9%, 10.4% and 26.0%, respectively. Around one in 10 had more than 
one allergic disease and the lifetime prevalence for any allergic disease was 45.1 %. More 
than 4 out of 10 participants were sensitized to at least one food or inhalant allergen. Nasal S. 
aureus carriage was found in half of the participants and was associated with the severity of 
allergic disease and allergic multimorbidity. Sensitization to staphylococcal enterotoxins was 
found in one fourth of the participants and was associated with allergic multimorbidity and 
poly-sensitization to food and inhalant allergens.  In the “Tromsø Fish Allergy Study”, we 
found tolerance to at least one fish species in 30% of fish allergic children regarding any 
allergic symptoms and in more than half regarding only objective allergic symptoms. 
Sensitization to standard fish allergen extracts and fish parvalbumins was found in nearly all 
participants, including participants with tolerance to certain fish species. Sensitization to 
species-specific enolase or aldolase was predominantly found in patients with objective 
allergic symptoms. However, sIgEs to enolase or aldolase were also negative in several 
patients with fish allergy. Specific IgE to cod extract >8.2 kUA/L or salmon extract >5.0 
kUA/L discriminated best between non-tolerance and tolerance to at least one fish species. 
Estimated threshold doses for cod were in line with previously published data, and estimated 
threshold doses were higher for salmon and mackerel compared to cod. 
 
Conclusions: 
Allergic diseases are common among adolescents in the Arctic region of Norway. S. aureus 
carriage may play a role in disease severity and allergic multimorbidity, whereas sensitization 
to staphylococcal enterotoxins may play a role in poly-sensitization to food- and inhalant 
allergens and allergic multimorbidity. Cross-reactivity between different fish species is 
common among fish allergic patients, but tolerance to some species exists in around one third 
and should be identified in order to avoid unnecessary food restrictions. A combination of 
clinical history and sIgE to fish-allergen extracts and molecules may reduce the number of 
food challenges needed for specific diagnosis of fish allergy. Threshold doses for allergic 






The overall topic of this thesis is allergic diseases in children and adolescents. More 
specifically, a major issue is to study associations to the development of multiple allergic 
diseases and sensitization to multiple allergens. Patients with multiple allergies may either be 
sensitized to several structurally unrelated allergens, be primary sensitized to one key allergen 
and cross sensitized to one or more structurally related allergen(s) or a combination of these 
two mechanisms may exist. In paper I and II, we studied associations between the bacterium 
Staphylococcus aureus and allergic diseases and sensitization to multiple allergens. The study 
also provides valuable novel knowledge about the prevalence of allergic disease among 
adolescents in the Arctic region of Norway. 
In paper III, we studied cross-sensitization and cross-reactivity to multiple fish species in 
children and adolescents with fish allergy. Fish allergic patients are commonly advised to 
avoid all species of fish. However, cross-sensitization may not necessarily result in clinical 
cross-reactivity. Furthermore, the gold standard in diagnosing food allergy, double-blind 
placebo-controlled food challenge (DBPCFC), is both time-consuming and potential harmful 
to the patient. Measurements of specific IgE (sIgE), together with skin prick test, are the 
primary methods for diagnosing sIgE-sensitization but these tests are less reliable than 
DBPCFC in diagnosing food allergy. In paper III, we also studied how sIgEs to fish allergen 
extracts and molecules perform in diagnosing fish allergy and/or tolerance compared to the 
results from DBPCFC. The study design also included a low dose DBPCFC protocol to allow 
us to estimate threshold doses for allergic reactions to different fish species. In the following 
part of the Introduction I will define and describe allergic diseases and concepts important for 
this thesis. 
1.2 Atopy 
“Atopy is a personal and/or familial tendency, usually in childhood or adolescence, to become 
sensitized and produce specific immunoglobulin E (sIgE) in response to ordinary exposures to 
allergens.”[1]. Atopy describes the genetic predisposition to become sIgE-sensitized to 
allergens commonly occurring in the environment, but to which the majority do not produce a 





Asthma is a heterogeneous disease, usually characterized by chronic airway inflammation. It 
is defined by the history of respiratory symptoms such as wheeze, shortness of breath, chest 
tightness and cough that vary over time and intensity, together with variable expiratory 
airflow limitation [2]. Although asthma is a chronic inflammatory disease, the natural course 
is characterized by intermittent exacerbations and reversibility of symptoms and airway 
obstruction. Viral infections, cold air, exercise, allergens, psychological stress, and air 
pollutants including tobacco smoke typically trigger exacerbations [3]. The pathogenesis of 
asthma is complex and incompletely understood. Different phenotypes have been suggested 
[4, 5], but it is unclear whether they represent different subgroupings of a single disease or are 
separate diseases within the syndrome of asthma. Allergic asthma is related to IgE-
sensitizations to inhaled allergens, whereas non-allergic asthma is also coined “intrinsic 
asthma”. Asthma may result in chronic persistent airway inflammation unrelated to allergen 
contact and has features of autoimmunity. Chronic inflammation has been associated with 
airway remodelling with  fixed airflow limitation as a result of “scarring” of the airways [6].  
There is no cure for asthma, but patients benefit from inhalation therapy with little side 
effects. In spite of available good therapy, many patients with more severe asthma or failure 
to adhere to treatment remain uncontrolled. Mild asthma attacks usually respond well to the 
inhalation of short acting beta2-agonists and persistent asthma to inhaled corticosteroids. 
Leukotriene-antagonists, long acting beta2-agonists, anticholinergic drugs, theophylline and 
anti-IgE-antibodies can be added in more severe or therapy refractory cases [3]. Asthma 
treatment is monitored by symptoms and use of reliever medication, exacerbation history, 
measures of airflow obstruction and biomarkers such as exhaled nitric oxide [2, 6]. Education 
of children with asthma and their parents is effective in improving clinically relevant 
outcomes. Adherence to maintenance medication and correct use of the inhaler device are key 
factors in obtaining asthma control. To monitor asthma, monitoring symptoms appears to be 
sufficient, whereas home monitoring of lung function does not improve health outcomes in 
asthmatic children [7]. 
1.4 Allergic rhinitis 
Allergic rhinitis is an inflammatory disorder of the nasal mucosa induced by an allergic 
immune response to inhaled allergens in sensitized individuals. The allergic immune cascade 
in the nasal mucosa may give rise to the following symptoms in a variable degree of severity 
 
13 
and duration: sneezing, itching, rhinorrhoea, or nasal congestion/obstruction, which 
frequently occur in conjunction with itchy, red and watery eyes (rhinoconjunctivitis). 
Symptoms may also affect the ears and throat and include postnasal drainage [8].  General 
symptoms like fatigue, impaired concentration and reduced productivity are all associated 
with allergic rhinitis. Eliciting allergens are most often pollens, animal dander, dust mites and 
mold spores, and symptoms may be seasonal (i.e. pollen allergy) or perennial (i.e. house dust 
mite allergy) [9].  Symptoms can be controlled by avoidance of the eliciting allergen(s) and 
by pharmacological therapies such as oral, intranasal and topical antihistamines, intranasal 
corticosteroids and leukotriene-antagonists, as mono-therapy or in combination [10]. Allergen 
immunotherapy is an additional potential treatment option, particularly for patients with more 
troublesome disease who remain inadequately controlled due to the allergen(s) being difficult 
to avoid and/or despite regular pharmacotherapy [10]. Allergic rhinitis and non-allergic 
rhinitis are independent risk factors for asthma, with the rhinitis frequently appearing prior to 
the asthma [11]. New methods for monitoring allergic rhinitis and asthma are now focusing 
on the implementation of emerging technologies for individualized and predictive medicine 
[12]. Mobile technology is developed for the management of rhinitis and asthma by a multi-
disciplinary group and by patients [13]. 
1.5 Atopic dermatitis  
Atopic dermatitis is a common skin disease often associated with other atopic disorders, such 
as allergic rhinitis and asthma. The clinical manifestations vary with age. It is a chronic, 
relapsing skin inflammation with disturbance of epidermal barrier function, dry skin and IgE-
mediated sensitization to food and environmental allergens. Itching, that worsens at night 
causes sleep loss and impaired quality of life, leads to scratching and crusted erosions [14]. 
Multiple triggers, i.e. allergens, climate, infections, psychological stress, irritants and others, 
influence on the course of the disease. Typically, symptoms arise during the first year of life 
with great tendency to outgrow the disease during childhood, but some patients continue to 
have atopic dermatitis during adolescence and adulthood  [15].  
The lesions of atopic dermatitis can affect any part of the body but typically show age-related 
morphology and distribution. No specific laboratory or histological findings are typical for 
atopic dermatitis, and thus the diagnosis relies exclusively on clinical features. Children with 
atopic dermatitis have increased risk of developing cutaneous S. aureus infections and 
cutaneous viral infections such as disseminated herpes simplex infections and molluscum 
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contagiosum [16]. Up to 90% of patients with atopic dermatitis are colonized with S. aureus 
on their skin surface [17].  
Filaggrin is a filament-associated protein that binds to keratin fibers in epithelial cells. It is 
important in the epidermal homeostasis, and filaggrin deficiency plays an important role in 
the pathogenesis of atopic dermatitis [18]. Filaggrin genotype, the skin microenvironment and 
environmental factors may contribute to decreased levels of filaggrin. Filaggrin deficiency 
increases the risk for microbial infection and development of other atopic diseases as asthma 
and rhinitis. Furthermore, cutaneous cytokine milieu or environmental influences including 
low humidity or mechanical damage are capable to secondarily modulate filaggrin expression 
[19].   
At present, there is no cure for atopic dermatitis. Thus, the aim of management is to improve 
symptoms and achieve long-term disease control with a multistep approach. The main 
principles are continuous epidermal barrier repair with emollients, avoidance of individual 
trigger factors, and anti-inflammatory therapy with topical corticosteroids or calcineurin 
inhibitors [20]. In severely affected cases, phototherapy or systemic immunosuppressants are 
indicated. Treatment failure due to poor adherence is common and doctors should spend 
sufficient time to explain the disease and its treatment. Written action plans might be helpful.  
A systematic review showed no preventive clinical benefit of anti-staphylococcal 
interventions such as antiseptic bath additives or soaps, or the addition of antimicrobial agents 
to topical therapies in non-infected atopic dermatitis [21]. However, in clinically 
superinfected atopic dermatitis, antiseptics may be sufficient to treat superinfected small 
areas, and are preferable to topical antibiotics with regard to the development of antibacterial 
resistance. More extensive superinfections often requires treatment with short courses of 
systemic antibiotics [21]. 
1.6 Allergic co-morbidity and the atopic march 
Atopic dermatitis, asthma and allergic rhinitis develop dynamically throughout childhood, 
and allergic co-morbidity is common [15, 22-25].  Having atopic disease in the family and/or 
having one atopic disease, greatly increases the risk of co-morbidity with other atopic 
diseases. A large number of studies from different continents have presented data on atopic 
co-morbidity. In the BAMSE birth cohort study in Stockholm, co-morbidity increased with 
age. At 12 years of age, at least two allergy-related diseases affected 7.5% of all the children 
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[22]. Parental allergy was associated with increased atopic co-morbidity and persistent atopic 
disease. Moreover, it increased the risk of having any allergy-related disease up to 12 years of 
age. These findings indicate that allergy-related diseases should be neither seen nor studied as 
isolated entities [22]. 
Patients with atopic dermatitis may develop a typical sequence of food allergy, rhinitis, and 
asthma, at certain ages, known as the atopic march (Figure 1) [16, 26, 27]. Atopic dermatitis 
and food allergies often start in the first year of life, followed by asthma triggered by viral 
infections, allergic asthma and allergic rhinitis by school age. IgE sensitization, early onset 
and severity of atopic dermatitis are the main risk factors for progression and persistence of 
asthma [26]. In a Norwegian study, participants with atopic dermatitis at two years had more 
asthma at six years of age compared to participants without atopic dermatitis at two years of 
age (OR 1.80, 95% CI 1.10-2.96) [28]. A defect in the epithelial barrier integrity may 
contribute to the onset of atopic dermatitis and progression of the atopic march [29].  
Figure 1. The atopic march.
 
The atopic march. Atopic dermatitis prevalence peaks early in infancy, probably opening the door for 
consequent development of the atopic march. Development of food allergy, asthma, and allergic rhinitis in the 
young toddler age group is common after cutaneous manifestations. The figure is printed with permission from 





1.7 Staphylococcus aureus 
1.7.1 Bacterial characteristics and virulence factors 
Staphylococci are Gram-positive, facultative anaerobic bacteria that grow most rapidly under 
aerobic conditions and in the presence of CO2. The Staphylococcus genus includes at least 40 
species, of which most are harmless and commensal bacteria on the skin and mucous 
membranes. Some staphylococci are able to produce the enzyme coagulase, an important 
feature used in classifications schemes of staphylococci. The by far most important and 
clinically relevant coagulase-positive Staphylococcus is S. aureus; a bacterium well equipped 
with potent virulence factors, survival fitness, and antimicrobial resistance determinants [30]. 
Some of the important virulence factors are staphylococcal enterotoxins (SEs); proteins with a 
common phylogenetic relationship, structure, function, and sequence homology. Over 20 SEs 
have been identified, including SE-A, SE-B, SE-C, SE-D, and SE-E [31]. SEs and 
staphylococcal enterotoxin-like molecules (collectively known as SAgs) are major virulence 
factors of S. aureus. Most S. aureus strains encode for and can produce SAgs when the 
opportunity arises [32]. 
1.7.2 Clinical aspects; infections and toxin-related disease 
S. aureus colonizes the nose and skin of approximately 50% of healthy individuals. Around 
80% of S. aureus infections are caused by the carrier strain already present on the skin or 
mucosa of the patient [33, 34]. The clinical presentation of S. aureus infections may vary 
from minor self-limiting soft tissue infections to a life threatening systemic disease. Infections 
encompass skin and soft tissue infections, muscle and visceral abscesses, septic arthritis, 
osteomyelitis, endocarditis, pneumonia, brain abscesses, meningitis and bacteremia, as well as 
toxinoses with toxic shock syndrome (TSS), scalded skin syndrome, and food poisoning [35]. 
S. aureus is the cause of a large proportion of bloodstream infections worldwide [36]. 
Decreased susceptibility to antibiotics is a major concern and methicillin resistant S. aureus 
(MRSA) is associated with higher mortality, morbidity and financial costs compared to 
methicillin-sensitive S. aureus [37]. 
S. aureus is a major food-borne pathogen worldwide and a frequent food contaminant causing 
food poisoning  by secretion of SE’s [38]. Common symptoms of food poisoning are nausea, 
vomiting, diarrhoea and abdominal cramps [31]. SE-A is most frequently involved in food 
poisoning [39], whereas SE-B also is identified as a potential biological weapon of war and 
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terrorism [40]. Most outbreaks of food poisoning are due to improper food handling either in 
the food industry or in the home.  
SAgs do not only cause vomiting and diarrhoea, but may also be highly lethal in humans [41]. 
They contribute to the pathophysiology in life-threatening infections with S. aureus, including 
sepsis, infective endocarditis, and necrotizing and haemorrhagic pneumonias. These 
infections have high mortality rates. Mortality is partly also dependent on the development of 
TSS, mediated by a complex interaction of SAgs with the host and resulting in extensive 
immune dysregulation and multi-organ dysfunction [41]. 
1.7.3 S. aureus carriage and allergic disease 
The nose, throat and skin are the major sites of S. aureus carriage [42]. In the majority of 
patients with atopic dermatitis the skin is colonized with  superantigen-encoding S. aureus. 
Furthermore, S. aureus abundance fluctuates and parallels clinical symptoms of atopic 
dermatitis. These observations have led to the “outside-inside model”, stating that genetic 
skin barrier defect compounded by a skin microbiota dysbiosis is the primary pathogenic 
event of atopic dermatitis [43].  
The role of infections and bacterial carriage in the pathogenesis of allergic rhinitis and asthma 
is less clear. Patients with allergic rhinitis have a high nasal carriage rate of S. aureus 
associated with aggravation of symptoms, possibly by promoting local IgE production to 
staphylococcal superantigens [44, 45]. There are conflicting data on a possible association 
between S. aureus carriage and asthma. In infants and preschool children, no clear association 
between S. aureus carriage and wheeze or airway inflammation has been shown so far [46]. 
However, in older children and adolescents S. aureus nasal carriage has been associated with 
increased risk of asthma and asthma exacerbations [47].   
1.7.4 Sensitization to S. aureus enterotoxins (SEs) and allergic disease 
SEs modulate the IgE isotype-switching leading to IgE sensitization to SEs [48]. IgE 
sensitization to SEs is associated with allergic disease. Local and/or systemic sIgE to SE may 
play a role in the development and/or disease severity of allergic disease [49-53]. SE-
sensitization is associated with asthma in adults and in the elderly, but an association has not 
yet been clearly demonstrated among children and adolescents [49, 50, 54, 55]. In the German 
MAS study they found a possible relationship between sensitization to SE and asthma at the 
age of 20 years (OR 2.5, 95% CI 1.3-4.7), but the difference between SE-sensitized and non-
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sensitized was no longer statistically significant after adjusting for potential confounders (OR 
1.6, 95% CI 0.80-3.4) [50]. In a GA
2
LEN study SE-sensitization was associated with asthma 
in adults (OR 2.10, 95% CI 1.60-2.76) and total IgE concentrations were higher in SE-
sensitized compared to non-sensitized [49]. In a systematic review and meta-analysis, SE-
sensitization was associated with asthma (pooled OR 2.95, 95% CI 2.28-3.82). Both children 
and adults were included in the review and rates of SE-sensitization increased with age and 
severity of asthma [56]. Some studies indicate an association between SE-sensitization and 
polyclonal allergen sensitization, reflected by higher total IgE levels among SE-sensitized 
individuals [49, 50]. However, the patterns and the magnitude of allergen poly-sensitization 
related to SE-sensitization have previously not been studied.  
1.8 Allergen 
An allergen is “a protein or glycoprotein capable of binding IgE”. Most allergens are derived 
from naturally occurring allergen sources. Allergenicity is related to the conformational 
structure of the folded protein recognized by the Fab part of the IgE molecule [57]. A protein 
consists of a defined amino acid sequence and a three-dimensional structure, but may have 
several variant proteins with slight differences in the amino acid sequence or with other small 
modifications [58]. Antigen determinants (epitopes) are localized regions on the surface of an 
antigen that are capable of binding IgE. Drugs, chlorhexidine and other pharmacological 
compounds are examples of non-protein allergens. The mucosal surfaces of the airways 
(inhalant allergens) and the digestive tract (food allergens) are the two most common sites of 
entry into the body. 
Allergen sources vary from highly complex structures such as pollen, animal hair and dander, 
house dust mites or foods to single molecules such as chemicals or drugs [59]. Protein 
families share common evolutionary origin reflected by similarity in the overall structure, 
topology and amino acid sequences. Allergen proteins are limited to a small number of 
protein families. Common examples are the 2S albumins in tree nuts, peanuts, legumes and 
seeds, the profilins in pollen from tree, grass and weed, fruits, vegetables and latex, the 
tropomyosins in crustaceans, molluscs and mites and the parvalbumins in fish.  
The nomenclature of allergens are standardized and based on the scientific name of the plant 
or animal species from which the allergen originates [60]. For example, the major allergen 
from Atlantic cod, Gad m 1, is named after the scientific name of the fish Gadus morhua, in 
which Gadus is the genus and morhua the species. The first three letters of the genus (Gad) 
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and the first letter of the species (m) together form the allergen name, followed by a number 
given in order of discovery of the allergen from the same allergen source. Different allergens 
from the same allergen source may represent different protein families; Gad m 1 is a 
parvalbumin, Gad m 2 an enolase, and Gad m3 an aldolase.  
In allergy testing the sensitization of a patients is often assessed according to whether sIgE 
binds to an allergen. These allergens may contain a mixture of many, and not completely 
purified allergens; in this thesis coined allergen extracts. Over the last two deacdes it has 
been possible to extract native allergens (components) from allergen sources, and to produce 
recombinant high purity allergens in the laboratory . These purified recombinant allergens, in 
this thesis coined allergen molecules, are currently used in the new diagnostic concept 
termed component resolved diagnosis (CRD). 
Cross-reactivity occurs when sIgE antibodies originally raised against one key allergen bind 
to a similar protein in another allergen, whereas co-sensitization describes multiple, unrelated 
sensitizations to several structurally unrelated allergen groups [61, 62]. Sensitizing allergens 
have the ability to induce allergen-specific IgE antibodies, whereas non-sensitizing allergens 
only can cause allergic symptoms if previous contact with a related (cross-reactive) allergen 
has caused sensitization. The birch pollen allergen Bet v 1 is a common sensitizer whereas the 
homologous apple allergen Mal d 1 is a non-sensitizer [63]. 
1.9 Fish Allergens 
Parvalbumin 
Parvalbumin, the major fish allergen, is a stable calcium binding fish muscle protein of low 
molecular weight, resistant to heat, chemical denaturation and proteolytic enzymes [64-67]. 
Aas et al identified the first fish parvalbumin, Gad c 1, in Baltic cod in the late 1960`s [64].  
Subsequently, parvalbumins from many fish species have been identified and described in 
detail [68-71]. By 2014, the official database of allergens, contained 21 parvalbumins from 12 
fish species and the Allergome database lists more than 100 entries for fish parvalbumins and 
their isoforms [72]. Only parvalbumin allergen molecules from carp and cod (Cyp c 1 and 





Figure 2. Cod parvalbumin with epitopes. Crystallographic illustrations kindly provided by 
Annette Kuhn. 
                             
 
Immunological cross-reactivity between parvalbumins 
Only beta-isoforms of fish parvalbumins are allergenic. High amino acid sequence homology 
in different fish species is the cause of cross-reactivity between species [73, 74]. However, 
some fish allergic patients may tolerate certain fish species [75-77], reflecting that 
heterogeneity in parvalbumin structure may cause differences in clinical allergic reactions to 
different fish species. In patients with cod allergy, sensitization to cod, salmon and pollock 
occur more frequently than sensitization to halibut, flounder, tuna and mackerel. IgE binding 
patterns are more similar among phylogenetic closely related fish species with parvalbumins 
of high amino acid sequence homology [73]. Even minor differences in amino acid sequence 
in salmon and trout parvalbumin, compared to other fish species, may result in mono-
sensitization to salmonid fish species [78]. Furthermore, regional differences in food culture 
may lead to different patterns of sensitization and different species of fish responsible for 
allergy [79].  
Parvalbumin content in different fish species 
The amount of parvalbumin in fish muscle is related to the allergenic properties. Parvalbumin 
levels differ considerable between fish species. In raw fish, parvalbumin levels decreases 
significantly in the following order: herring > carp > redfish > salmon/trout > cod > mackerel 
> tuna. The difference between herring and tuna vary by a factor of 100 [80]. Parvalbumin 
content also differs in different parts of a fish. Parvalbumin content in dark muscle is  
significantly lower than in white muscle, and dark fish muscle is much less allergenic than the 
white muscle [81]. Tuna parvalbumin is only measurable in the white tissue muscle [80]. 
White muscle is used for rapid movements and dark muscle for continues swimming. Active 
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fish species, such as tuna and mackerel, have a higher proportion of dark muscles than bottom 
dwelling fish species, such as cod and flounder that have high contents of white muscle. 
 
Stability of parvalbumins 
The stability of proteins is a characteristic that affects the allergenic properties of an allergen. 
Unstable proteins are denatured during processing of food or soon after ingestion. 
Consequently, they are less allergenic than stable proteins that conserve their structure during 
processing and digestion. Parvalbumins are highly stable proteins resistant to heat, chemical 
denaturation and proteolytic enzymes [64, 73]. However, parvalbumin levels are lower in 
processed food such as pickled, canned or smoked fish due to protein denaturation caused by 
processing conditions such as low pH, high pressure and high temperature. Simple boiling is a 
mild food processing reaction that does not change parvalbumin content considerably [80]. As 
a result, most fish-allergic patients have allergic reactions after ingestion of cooked fish. 
Allergens are even conserved and transported as airborne particles in vapour from cooking 
and fish allergic patients may experience allergic reactions after inhalation of allergen 
aerosols [82]. 
Parvalbumin and specific allergen immunotherapy 
So far, no allergen immunotherapy is available for treating fish allergy. Recombinant carp  
parvalbumin is by some researchers regarded as a major cross-reactive fish allergen and a 
possible tool for both diagnosis and immunotherapy of fish allergy [74]. A hypoallergenic 
drug product with conserved immunogenicity based on recombinant carp parvalbumin  (rCyp 
c 1) has been developed, and from 2015 studied in a safety phase I/IIa clinical trial on 
immunotherapy in fish-allergic patients [83]. 
 
Enolase and aldolase. 
Kuehn et al identified enolases and aldolases, native oligomers which are labile to thermal 
treatment, as important fish allergens in cod, salmon and tuna [84]. She also suggested that 
fish-allergic patients may be divided into three clusters based on their IgE sensitization 
patterns to fish allergen molecules. In the first cluster (58.1 %), patients were sensitized to all 
three parvalbumins, and a significant proportion to enolase (80.6 %) and aldolase (58.3 %). 
These patients were allergic to multiple fish species. In the second cluster (14.5%), most 
patients were sensitized only to salmon parvalbumin. These patients reported clinical 
reactivity exclusively to salmon and with milder symptoms than patients in the first cluster. In 
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the third cluster (27.4 %), patients were not sensitized to parvalbumins, but reported clinical 
reactivity to one or several fish species. Specific IgE’s to enolase, aldolase or fish gelatin 
were detected in 70% of patients in the third cluster. Their allergic symptoms ranged from 
mild to severe and 76% reported tolerance to single fish species. Interestingly, five patients in 
this study [84] reacted to still unidentified allergens assumed by the presence of IgE-reactive 
bands in immunoblot. The authors concluded that a high proportion of fish-allergic patients 
are not sensitized to parvalbumin and the use of additional allergens such as enolase, aldolase 
and possibly fish gelatin may be of great importance. However, the clinical significance of 
these allergens should be further assessed in studies were sIgE reactivity is compared with 
results from oral food challenges with different fish species [84]. 
Collagen/Gelatin. 
Hamada et al identified collagen as a possible important fish allergen [85]. Native collagen is 
composed of three α-chains twisted together in a triple helix and is found as a large 
extracellular matrix protein in animals. Collagen is denatured to a mixture of protein 
fragments (gelatin) by heating and digestion with muscle proteases. There is no antigenic 
cross-reactivity between collagens from fish and other animals, indicating that fish collagen 
contains IgE-binding epitopes with amino acid sequences, which are not found in collagen 
molecules from other animals. However, IgE cross-reactivity to heated extracts from five 
species of fish indicates that collagen is commonly allergenic regardless of fish species. 
Sakaguchi et al also found that some fish-allergic patients showed IgE reactivity to fish 
gelatin and concluded that fish gelatin might be an allergen in fish allergy [86]. In another 
study, only three of 100 serum samples from fish-allergic or fish-sensitized patients gave 
evidence of reactivity to gelatin extracted from tuna skin [87]. In a randomized, double-
blinded, placebo-controlled oral challenge with fish gelatin, none of 30 fish allergic patients 
reacted adversely to a cumulative dose of 3.61 g gelatin [88]. The relevance of fish gelatin as 
a food allergen is therefore still controversial and the results from studies are diverging. 
Meanwhile, fish gelatin used in the food industry is increasing since bovine and porcine 
gelatin used as additives in vaccines have been linked to anaphylactic reactions. In a case-
report, a 12-year-old boy had a severe anaphylactic reaction after ingestion of marshmallows 
containing fish gelatin. He was allergic to different fish species and sensitized to tuna, salmon 





Other fish allergens. 
Vitellogenin is identified as an allergen in Beluga caviar allergy and several case-reports on 
allergy to fish roe has been reported [90]. 
Fish allergens; diagnose and treatment of fish allergy. 
The allergenic properties of a wide number of fish allergens are characterized in detail. 
However, this knowledge has not yet resulted in significant improvements when it comes to 
diagnosing and treating fish allergy. We still depend on oral food challenges to establish a 
clear diagnosis in many patients and avoidance of the offending allergen is still the only 
clinical approach available. The ongoing trials with specific allergen immunotherapy with 
hypoallergenic carp parvalbumin may be a step forward in the treatment of fish allergy [83]. 
More research is needed to address the role of parvalbumin, enolase, aldolase, gelatin and 
other possible fish allergens. One aim is to develop more precise diagnostic tools to better 
discriminate between allergy and tolerance to different fish species, and thereby avoid 
unnecessary food restrictions. Another aim is to develop effective and safe allergen 
immunotherapy that can induce tolerance to fish in fish-allergic patients. 
1.10 Food allergy  
Adverse reactions to foods include different reactions with different mechanisms including 
toxic, enzymatic and hypersensitivity reactions. Food allergy refers to the subgroup of food 
hypersensitivity reactions in which immunologic mechanisms have been demonstrated. An 
US expert panel defined food allergy as ‘‘an adverse health effect arising from a specific 
immune response that occurs reproducibly on exposure to a given food’’, and food intolerance 
as “non-immune reactions that include metabolic, toxic, pharmacologic, and undefined 
mechanisms” [91]. A food intolerance occurs when a person has difficulty digesting a 
particular food. This can lead to symptoms such as intestinal gas, abdominal pain or 
diarrhoea. Food intolerance is sometimes confused with or mislabelled as food 
allergy. However, food intolerances mainly involve the digestive system whereas food 
allergies involve the immune system. With a food allergy, even a very small amount of the 
food has the potential to lead to anaphylaxis. The most common food intolerances are lactose 
intolerance and gluten intolerance. Symptoms from food intolerance and allergy may still be 




Food allergies may be IgE mediated, non-IgE mediated, or a combination of both. IgE 
mediated food allergies most often cause immediate symptoms and have the potential to cause 
anaphylaxis. Non-IgE mediated food allergies are cell mediated with more delayed 
symptoms. The pathophysiology of both mechanisms is through food antigen sensitization 
and Th2 skewing of the immune system [92]. Food allergies are believed to be a result of 
either loss of oral tolerance or the failure to induce tolerance. The mechanisms of the 
development of oral tolerance is a complex interaction between ingested food proteins and 
antigen-presenting cells leading to suppression of cellular and humoral immune responses 
[93]. Non–IgE-mediated immunologic reactions include food protein–induced enterocolitis, 
proctocolitis, and enteropathy syndromes that primarily affect infants or young children. The 
symptoms are vomiting, abdominal cramps, diarrhoea, and occasionally blood in the stool and 
failure to thrive or poor weight gain. Eosinophilic esophagitis and atopic dermatitis are 
examples of co-morbidities with mixed IgE- and non–IgE-mediated causes.  
The clinical presentation of food allergy may involve symptoms from the skin (urticaria, 
angioedema, and atopic eczema), the gastrointestinal tract (vomiting, abdominal pain, 
diarrhoea, and constipation), the respiratory tract (rhinorrhoea, sneezing, cough, and 
dyspnoea) and the circulation (hypotension and cardiac collapse). Reactions are elicited by 
food ingestion, inhalation of vapour from cooking, or skin contact [94]. The most common 
food allergen sources are egg, milk, peanuts, tree nuts, soy, wheat, shellfish, and fish [95]. 
Childhood food allergies to egg, milk, wheat and soy typically resolve during childhood, 
whereas allergies to tree nuts, peanuts, shellfish and fish most often are persistent [96].  
Depending on the route of sensitization, food allergies are either a result of reactivity to 
ingested allergens or the result of secondary sensitization to cross-reactive inhalant allergens 
due to primary sensitization to homologous pollen allergens via the respiratory tract [97]. The 
former group of allergens are often resistant to heat, degradation and digestion, whereas the 
latter group are mainly labile and easily degradable. The type of allergens to which an 
individual is sensitized influence the clinical manifestation. Primary sensitization to food 
allergens has the potential to induce more severe reactions compared to food allergies due to 




1.11 Prevention of food allergy 
Different strategies for prevention of food allergy have been recommended. The American 
Academy of Paediatrics recommended in 2000 that infants at higher risk of allergy should 
delay the introduction of ‘more allergenic’ foods in their diet, including avoidance of eggs 
until two years, fish and nuts until three years of age [98]. Since then, increasing evidence has 
shown that early introduction of solid food in fact may prevent development of allergies [99-
102], whereas late introduction is associated with increased risk of allergy [99, 100]. In a 
recent review the authors concluded that the findings of dietary interventions to prevent 
allergy are unconvincing, inconsistent or not adequately tested and that numerous questions 
remain about how to implement early food introduction, and which groups of infants should 
be targeted [105]. However, it is clear that the paradigm has shifted from recommending 
avoidance of common food allergens in infancy, to consideration of early consumption 
strategies to prevent allergy development.  
Several studies have also tried to restore a more “healthy” gut microbiota by giving 
probiotics, either as a supplement or in infant foods in order to reduce allergy [103]. A 
moderate benefit has been reported for the prevention of atopic dermatitis, but no preventive 
effect has been shown for other allergic disease [103] . So far, no expert bodies do generally 
recommend probiotics for allergy prevention. However, a recent meta-analysis shows some 
protective effect on developing atopic disease (RR 0.71; 95% CI 0.57-0.89) and food 
hypersensitivity (RR 0.77; 95% CI 0.61-0.98) if probiotics were administered prenatally to 
the pregnant mother and postnatally to the child. When probiotics were administered either 
only prenatally or only postnatally, no effects on atopy and food hypersensitivity were 
observed [104].  
1.12 Fish allergy 
Fish is an important healthy human nutritive but also one of the most common food allergen 
sources, together with milk, egg, peanuts, tree nuts, soy, wheat, and shellfish [106]. 
Sensitization to fish starts during childhood and patients often remain allergic throughout 
their life. Fish and shellfish are among the food groups most commonly provoking severe 
food anaphylaxis [107]. Fish allergy is especially prevalent in fish-eating, fish-processing and 
coastal countries like Norway, Greece, Spain and Japan. The prevalence of fish allergy varies 
between 0.1% and 2.2% in different countries measured with different methods [106, 108]. In 
one survey of parents in Norway, adverse food reactions were reported in 35% of their 
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children, nearly 3% of whom had a reported reaction attributable to fish by the age of two 
years [109]. Studies based on sensitization to allergens and in particular studies based on self-
reported allergy, tend to overestimate the prevalence of clinical allergy. 
Symptoms of fish allergy range from oral pruritus, urticaria, angioedema, nausea, abdominal 
pain, vomiting, diarrhoea, and asthma to systemic anaphylaxis in some cases. Symptoms can 
be elicited by ingestion, inhalation of vapour from cooking and skin contact. Exposure to high 
concentrations of fish allergens in the fish industry is a high-risk factor for occupational fish 
allergy. IgE mediated fish reactions are most common and appear within minutes to an hour 
after exposure. Fish can also be the cause of food-dependent exercise-induced anaphylaxis 
[110], and may be the cause of food-protein-induced enterocolitis syndrome (FPIES), a non 
IgE-mediated reaction mainly in young children [111].  
Clinical cross-reactivity between fish species is very common and patients with fish allergy 
are often advised to avoid all fish species. In a Norwegian study, ten adult patients with a 
clear history of fish allergy and sensitization to fish allergens, were tested regarding 
sensitization to recombinant parvalbumin from cod, salmon and mackerel. The study showed 
that cod, salmon, pollock, herring and wolfish contained the most potent cross-reacting fish 
parvalbumins, whereas halibut, flounder, tuna and mackerel were the least allergenic. No food 
challenges were performed because of previous severe reactions/anaphylaxis [73].  
Only a few small clinical trials have studied cross-reactivity using DBPCFC with different 
fish species. Bernhisel-Broadbent studied eleven children and young adults, and only two 
(18%) had objective reactions to all three fish species tested [75]. In this study, the utility of 
fish extracts in the diagnosis of fish allergy was investigated both by using skin prick test 
(SPT) and by measure of specific IgE to fish allergen extracts. They concluded that SPT and 
in vitro evidence of IgE-specific cross-reactivity not necessarily correlate with symptomatic 
fish allergy. They did not use the new fish allergen molecules for sIgE testing. Helbling 
studied nine participants with fish allergy, and only three (33%) experienced objective 
symptoms to all three fish species [77]. Compared to the positive challenges, predictive 
accuracy of skin prick test and specific IgE with fish allergen extracts was 84% and 78%, 
respectively. They concluded that clinically relevant cross-reactivity among various species of 
fish might exist, and advised fish-allergic subjects to avoid all fish species until tolerance to 
specific species can be proven safe by food challenge. 
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In a study based on self-reported fish allergy, Swoboda et al have shown that recombinant 
parvalbumin from carp fish reacted with IgE from all fish-allergic patients tested (n=60), 
induced specific and dose-dependent basophil histamine release, and contained most of the 
IgE epitopes present in natural allergen extracts from cod, tuna and salmon. They therefore 
concluded that carp parvalbumin can be used to identify patients suffering from IgE-mediated 
fish allergy in general [74]. However, the high degree of cross-sensitization with 
parvalbumins from other fish species makes it a poor test in order to identify clinical tolerance 
to some fish species.  As for other food allergies, there is no cure for fish allergy, and patients 
have to avoid fish in their diet. 
Threshold dose distributions for fish species have only been published for cod in the 
EuroPrevall project [112]. Estimated dose eliciting a reaction in 10% of the study population 
(ED10) for cod protein was 0.2 mg (95% CI 0.005-8.2) for subjective symptoms and 27.3 mg 
(95% CI 5.3-171.2) for objective symptoms. No estimates have so far been published for 
other fish species, thus data are lacking as to whether threshold doses may vary between 
different fish species. 
1.13 Anaphylaxis 
Anaphylaxis is a severe, life-threatening generalized or systemic hypersensitivity reaction, 
affecting around 1 in 300 of the European population at some time in their lives. A consensus 
clinical definition states that anaphylaxis is highly likely when any of the following three 
criteria is fulfilled [113]: 
1. Acute onset (minutes to several hours) with involvement of the skin, mucosal tissue, or 
both (e.g. generalized hives, pruritus or flushing, swollen lips–tongue–uvula), and at least one 
of the following: 
a. Respiratory compromise (e.g. dyspnoea, wheeze, stridor, reduced peak expiratory flow   
(PEF), hypoxemia) 
b. Reduced blood pressure (BP) or symptoms of end-organ dysfunction (e.g. syncope) 
2. Two or more of the following that occur rapidly after exposure to a likely allergen:  
a. Involvement of the skin–mucosal tissue (e.g., hives, flushing, swollen lips–tongue) 
b. Respiratory compromise (e.g. dyspnoea, wheeze, stridor, reduced PEF, hypoxemia) 
c. Reduced BP or associated symptoms (e.g. collapse, syncope, incontinence) 
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d. Persistent gastrointestinal symptoms (e.g. crampy abdominal pain, vomiting) 
3. Reduced BP after exposure to known allergen for that patient (minutes to several hours): 
a. Infants and children: low systolic BP (age specific) or > 30% decrease in systolic BP 
b. Adults: systolic BP of < 90 mmHg or > 30% decrease from that person’s baseline. 
In a systematic review on anaphylaxis in Europe, the key triggers were foods, medications, 
stinging insects and latex [114]. However, in up to 20% of cases the elicitor is not identified. 
Foods are the most frequent cause of anaphylaxis in children, with pollen allergy and asthma 
being important risk factors [114]. In central Europe the most common elicitors in a mixed 
child- and adult population were insect stings (50%), food (24%) and drugs (17%) [115]. 
Among food elicitors, the most common were peanuts and legumes (21.5%), followed by 
animal derived food (20.3%; cow`s milk, hen`s egg, fish, shellfish and meat), tree nuts 
(19.7%), vegetables (7.8%) and fruits (7.4%). Co-factors may increase the risk of an allergic 
reaction occurring or the severity of the reaction. Co-factors have been described in nearly 
20% of young patients in a prospective register-based study [116]. They include exercise, 
fever, acute infection, premenstrual status and emotional stress. Non-steroid anti-
inflammatory drugs (NSAIDs) and alcohol also seem to enhance some food allergic reactions. 
Exercise is a mandatory factor in exercise-induced anaphylaxis (EIA) and food-dependent, 
exercise-induced anaphylaxis (FDEIA) which are more common in adults than in children. 
The association with exercise is crucial for the onset of symptoms or signs, but EIA is not 
fully reproducible so that the same exercise may not always result in anaphylaxis [114].  
Intramuscular adrenaline is the first-line-intervention for  anaphylaxis, followed by oxygen, 
fluid support, inhaled beta2-agonists, systemic antihistamines and oral or intravenous 
glucocorticosteroids [117]. 
1.14 Atopic disease, heredity and epigenetic regulation 
The risk of a child developing an IgE-mediated allergy is 40–60% if both parents have atopic 
disease compared to 5–10% if neither of the parents have atopic disease. Associations 
between several gene loci and asthma, high IgE levels, and other allergic conditions have 
been reported. However, no single specific genetic marker for atopy has been identified, 
indicating that atopy is a complex polygenic disorder, influenced by multiple disease genes 
[59, 118]. Atopic diseases are the result of complex interactions between genetic 
predisposition and environmental factors. Epigenetic regulation is the exposures to 
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environmental, nutritional, and lifestyle factors that contribute to either disease development 
or protection by directly or indirectly modulating and modifying the accessibility of the gene 
transcription machinery. One such mechanism is CpG methylation directly occurring on the 
DNA sequence, whereas other mechanisms operate on the chromatin structure, such as 
biochemically modified histone protein tails which subsequently allow or deny access of 
transcription factors to gene promoter regions [119]. Microbes play an important role early in 
life, and allergy protection has been associated with exposure to or growing up in traditional 
farming environment [120]. Exposure to microbes in early childhood is also associated with 
lower risk of respiratory allergic disease later in life. These protective effects are most likely 
partly mediated through epigenetic modifications. 
1.15 Prevalence of atopic disease 
In recent decades, there has been a worldwide increase in prevalence of asthma and allergic 
diseases with different regional patterns. The highest prevalence’s are seen in western, high-
income countries. Worldwide time trends indicate that international differences are decreasing 
with increase in low-income countries in Africa, Latin America and parts of Asia and 
decrease in some western countries [121]. However, asthma continues to be a major public 
health concern worldwide [122]. In the BAMSE cohort study in Stockholm, 58% of the 
children had had atopic dermatitis, asthma and/or  allergic rhinitis at some time by the age of 
12 years [22]. Between four and eight years of age the proportion of children sensitized to any 
of eight inhalant allergens increased from 15% to 25% [123]. In a recent study using 
population based incidence rates in Denmark and Sweden, atopic dermatitis, asthma and 
allergic rhinoconjunctivitis affect nearly one third of the children at five years of age. Time 
trends showed the incidence of atopic dermatitis to be stable, the incidence of asthma 
increasing in Sweden, but decreasing in Denmark, and the incidence rate of allergic 
rhinoconjunctivitis to be decreasing [124]. In a Dutch population-based cohort study, the 
incidence rate of physician-diagnosed asthma in children was 6.7 per 1000 person year from 
2000 to 2012. The asthma incidence was increasing until 2008, but showed a non-significant 
decrease from 2008-2012 [125]. In a Norwegian birth cohort study, the lifetime prevalence of 
asthma was 20.2% and allergic sensitization 29.3% [126]. In the northern subarctic region of 
Norway, increasing prevalence of asthma, allergic rhinoconjunctivitis and atopic dermatitis 
among school children were shown in three surveys during the period 1985-2008. Prevalence 
of asthma increased from 7.3% to 17.6% and allergic rhinoconjunctivitis from 15.9% to 
24.5% [127, 128]. Within this region, major differences were shown between Russian and 
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northern Norwegian school children [129]. Atopic diseases were reported in 38.7% of 
Norwegian children versus 24.2% of Russian children, atopic dermatitis in 23.9% versus 
7.9%, allergic rhinitis in 20.6 % versus 14.7% whereas self-reported asthma was similar in 
both areas, 12.3% versus 13.1%.  
Prevalence’s of allergy-related diseases tend to decrease during adolescence. In the 
Norwegian birth cohort study there was a decrease in bronchial hyper-responsiveness 
measured with metacholine challenges between the ages of 10 and 16 years [130]. However, 
in  Uppsala the estimated prevalence of exercise-induced bronchoconstriction in a cross-
sectional study among 12-13 years old adolescents was as high as 19.2% [131]. Despite 
increasing incidence of asthma, hospital admissions due to asthma exacerbations decrease, 
probably due to improved care of children with asthma or a real reduction in asthma 
exacerbations [132]. 
Food allergy varies by age groups and regions and there is a marked difference between self-
reported and challenge-verified prevalence of food allergy. In a prospective study from birth 
to the age of two year, the cumulative incidence of parent reported adverse reactions to food 
was 35% [109]. In a systematic review and meta-analysis of food allergy in Europe the 
overall lifetime prevalence of self-reported food allergy was 17.3% [106]. Point prevalence 
for self-reported food allergy (5.9%), positive skin prick test to at least one food (2.7%), 
positive sIgE (10.1%) but challenge-verified food allergy (0.9%) were lower. The highest 
prevalence was seen in North Western Europe and in children compared to adults. Low 
prevalence of self-reported and confirmed food allergy was found in Southern Europe, while 
sensitization was similar to other regions. Highest prevalence in children is for cow´s milk 
where the pooled lifetime self-reported prevalence is 6% and the point self-reported 
prevalence 2.3 %. Prevalence of allergy to cow`s milk and egg is higher in younger age 
groups and allergy to peanut, tree nut, fish and shellfish higher in older age groups and in 
Northern Europe. Although data on the time-trends of food allergy were weak, the prevalence 
appeared to be increasing [106]. Moreover, progression of sensitization may shift from foods 
of animal and plant origin over to pollen and animal allergens during childhood [123]. 
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1.16 Diagnostic work-up of food allergy 
1.16.1 Clinical history and examination 
Knowledge about route of exposure, type and severity of symptoms and a careful dietary 
history is fundamental for the diagnosis of food allergy [94]. The history may identify the 
potential allergen source and indicate whether an IgE mediated or non-IgE mediated 
mechanism is involved. The clinical examination should include nutritional status and growth, 
especially in children, as well as examination for other atopic diseases. In relation to an 
ongoing allergic reaction, attention should be on examination of the skin and oral cavity, the 
gastro-intestinal, respiratory and circulatory systems. 
1.16.2 Skin prick test and serum specific IgE tests. 
Skin prick test and serum specific IgE are the first-line tests to assess IgE sensitization. 
However, these tests cannot accurately diagnose food allergy since sensitization to an allergen 
may exist without the patient experiencing allergic symptoms after exposure to the same 
allergen. It is of crucial importance that the results of these tests always are interpreted in 
relation to the clinical history, and the diagnosis of food allergy should not be based on the 
results from these tests only. The skin prick test is performed on the forearm or on the upper 
back. Negative and positive controls are required and the maximum wheal diameter is 
reported with a positive cut-off diameter ≥ 3 mm after 15 min [133]. There are numerous 
variables to be considered (e.g. lancet type, recording of wheal diameter, age, sex, site of 
testing), and only trained health care professionals should perform and interpret the results of 
the skin prick test [133]. 
The discovery of IgE in 1967 [134], allowed researchers and allergists to improve the 
diagnosis of IgE-mediated diseases. The first generations of IgE-assays were based on 
allergen extracts, which is a mixture of allergenic and non-allergenic compounds derived 
from natural sources (e.g. a pollen extract). They are still widely used in the diagnostic work-
up of allergies. However, because extracts contain a mixture of allergens from an allergen 
source, they cannot tell to which specific allergen an individual is sensitized. Over the last 
two decades, an increasing number of allergen molecules have been identified and used in the 
new diagnostic concept termed component resolved diagnosis (CRD) of allergy. CRD 
provides a more individualized and stratified diagnosis and improves the sensitivity, 
specificity and clinical performance of the laboratory assay. It has the potential to better select 
patients for immunotherapy, to predict the risk for severe allergic reactions and to monitor 
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patients for immunotherapy outcome. During the last decade, parallel diagnosis on hundreds 
of allergen molecules from a large number of allergenic sources has also become available as 
a multiplex microarray test [135].   
1.16.3 Diagnostic sIgE work-up strategies [136]. 
From symptoms to molecules: The “top-down approach”: 
Current guidelines recommend that the diagnostic work-up should be primarily guided by the 
clinical history, rather than to start with random screening for IgE sensitization. Allergen 
extract-based skin prick testing and/or serum sIgE-testing are usually enough to identify or 
exclude sIgE-sensitizations to potentially involved allergen sources. This may give either a 
negative result, a restricted sIgE antibody response sufficient to identify the underlying 
allergen source or many positive results to inhalant or food allergens extracts. In case of  
many positive results, further work-up (“top-down approach”) with specific allergen 
molecules may identify the most important molecular IgE sensitizations. 
From molecules to symptoms: The “bottom-up approach”: 
In this approach the diagnostic work-up start with analysing the entire IgE repertoire and then 
ask the patient for symptoms in order to identify the relevant sensitizations. However, for 
several reasons, this is currently not an appropriate diagnostic approach; not all allergens are 
available for diagnostic purposes, it will be too expensive, give too much information to 
process and interpret, and it will generate a large number of positive test results without 
clinical relevance. 
“Top down and bottom up”, the “U-shaped approach”: 
If the “top-down approach” leaves open questions regarding the implications of potentially 
cross-reactive allergens after one key allergen has been identified, the “bottom-up approach” 
can be applied only for relevant cross-reacting protein families depending on the initial 
findings. This approach explores the degree and potential clinical relevance of cross-reactivity 
to related molecules of a protein family [136]. 
1.16.4 Elimination diet. 
A diagnostic elimination diet is avoidance of the food(s) suspected of triggering allergic 
reactions based on the clinical history, diet history, and allergy testing such as skin prick 
testing and sIgE. The duration of the avoidance is usually 2–4 weeks for IgE-mediated 
symptoms and longer for non-IgE mediated symptoms. Symptoms are monitored and results 
 
33 
evaluated to establish or refute the food allergy diagnosis. The avoidance phase should be 
followed by a planned reintroduction of the eliminated food(s). A reported clinical reaction 
should be confirmed by oral food challenge (OFC) under medical supervision [117]. 
1.16.5 Oral food challenges (OFC) 
Oral food challenges are used to confirm the diagnosis of food allergy, to monitor food 
allergy, or to prove oral tolerance to a given food. Guidelines include patient selection, safety 
criteria, type and quantity of the food allergen to be administered, timings between doses, 
outcome criteria, observation periods, and recipes to be used [137]. Challenges can be 
performed open or blinded. Blinded challenges can be single or double-blinded and also 
include placebo [117]. In most clinical settings, an open OFC with an objective allergic 
reaction is sufficient for the diagnosis of food allergy. DBPCFC is the gold standard 
diagnostic test for the diagnosis of food allergy. If negative, the result has to be confirmed by 
a negative open OFC of a regular age-appropriate serving or the cumulative dose of the 
previous challenge. 
DBPCFC is better than open OFC in patients with atopic dermatitis and only subjective or 
suspected psychological symptoms. DBPCFC is also the gold standard in research settings 
[138]. During a DBPCFC the food is blinded for taste, smell and texture, and the appearance 
of placebo and the active food should be indistinguishable from each other. The food is served 
in titrated doses, at set intervals and challenges stopped if objective clinical reactions are 
observed or the last dose is consumed without clinical symptoms. Immediate reactions usually 
appear within 2 h after the last food intake, but atopic dermatitis may worsen several hours or 
days following an oral challenge. The most common objective signs are urticaria and 
angioedema, but gastrointestinal, respiratory or cardiovascular system involvement is also 
common. Vital signs should be closely monitored during both open OFC and DBPCF. 
Necessary equipment and drugs, and appropriately trained staff should be in place to deal 
with allergic reactions including anaphylaxis [117]. 
1.16.6 Cellular allergy testing. 
Cellular testing is used when the patient history and specific IgE or skin prick tests are 
discordant, when there is no reliable specific IgE or skin test, or if the patient history indicates 
that oral challenges or skin tests may elicit a systemic response [59]. The most common test is 
the basophil activation test (BAT) with determination of basophil sensitivity with serial 
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dilutions of allergen to measure the point of inflection of an allergic response [139]. Basophil 
sensitivity can be used to identify food allergens, the primary sensitizer amongst cross-
reacting allergens or allergen preparations and to monitor progress of allergen immunotherapy 
and anti-IgE therapy. Basophil activation is measured as either histamine release or as up-
regulation of granule proteins to the cell surface in response to allergen exposure.  
1.17 Precautionary allergen labelling 
Precautionary allergen labelling (PAL) was introduced by the food industry to help manage 
and communicate the possibility of reaction from the unintended presence of allergens in 
foods. Common labels are “may contain” or “may contain trace amounts of allergen”. 
However, in its current form, PAL may be confusing for consumers with food allergies. 
Knowledge about threshold doses needed for eliciting allergic symptoms are lacking, 
resulting in inconsistent application of PAL, giving a poor relationship between the presence 
or absence of PAL and the actual risk of allergic reaction. Consequently, food allergic patients 
do not know if they can trust in PAL, reducing the possibility to make informed choices. The 
result has been reduced avoidance, reduced quality of life and increased risk-taking by 
consumers who often ignore PAL [140]. 
1.18 Hypotheses of allergy development 
Strachan proposed the hygiene hypothesis in 1989 based on a national British birth cohort 
study, following 17 414 children to the age of 23 years [141]. He suggested that allergic 
diseases were prevented by infections in early childhood. Later infection or re-infection by 
younger siblings might result in additional protection against hay fever. Declining family size, 
improvements in household amenities, and higher standards of personal hygiene reduced the 
opportunity for cross-infection in young families. The result being more widespread clinical 
expression of atopic disease [141]. Later studies have shown protection against asthma and 
allergies after exposure to traditional farming environment in childhood [120, 142, 143].  
The biodiversity hypothesis extends on the hygiene hypothesis. Biodiversity is defined as the 
variability among living organisms from all sources, both the macro- and micro-levels. Loss 
of macro-diversity, give also a lesser micro-diversity, which is associated with alterations of 
the microbiota. Reduced biodiversity and alterations of the gut and skin microbiota are 
associated with inflammatory diseases, including asthma, allergic and inflammatory bowel 
disease, type I diabetes and obesity. The cross-talk between human DNA and environmental 
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DNA determines the capability of the human immune system to make the difference between 
danger and non-danger, and the difference between self and non-self [144]. Ongoing and 
future studies will give more knowledge about the gut microbiota and the role of microbes in 
health and disease. Future guidelines for disease prevention and treatment of allergic diseases 
will also address how this may be achieved by influencing the gut microbiota [145].  
Recently, Bousquet et al published “The MeDALL” hypothesis [146]. Allergic 
multimorbidity is associated with IgE poly-sensitization. The authors hypothesized that 
persistence or re-occurrence of foetal type 2 signalling genes plays an important role in the 
development of allergic multimorbidity and IgE poly-sensitization. Epigenetic mechanisms 
induced by environmental factors activate genes regulating these processes. Allergens and 
environmental cofactors (nutritional, bacterial and viral infections, microbiota) act at different 
times in pregnancy and the life cycle in subjects with a variable genetic predisposition to 
develop an IgE-mediated disease (Figure 3). Of special interest for this PhD-thesis is the fact 
that staphylococcal carriage/infection and sensitization to SEs are suggested to be one of 
many environmental factors that can play a role in children and adolescents. 











Published with permission from Jean Bousquet. 
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1.19 Impact of atopic disease 
1.19.1 Impact of atopic disease on quality of life 
Symptoms and signs from allergic diseases vary from very mild to life threatening. Moderate 
to severe symptoms affect the quality of life for a large number of patients. Patient-assessed 
severity of atopic dermatitis correlates with lower quality of life, indicating a greater 
impact with greater disease severity [147]. There is no cure for food allergy and so far, 
avoidance of the offending food is the only way to avoid allergic reactions. Anxiety for 
hidden allergens in food is common, especially when eating outside home [148]. In fact, 
the anxiety associated with the risk of a potential reaction has more profound effects on 
emotional and social aspects of a child’s everyday life than clinical reactivity induced by 
food intake [149]. Most patients and parents to children with food allergy are aware of 
what to eat and not to eat, resulting in low morbidity due to their food allergy. However, 
there is strong evidence that food allergy has an impact on psychological distress and on 
the quality of life of children and adolescents, as well as their families [150, 151]. 
Asthma also has a significant impact on quality of life, both for children, adolescents and 
parents. A recent meta-analysis of 15 quantitative studies with 1797 asthma patients 
showed lower overall quality of life, physical functioning, psychological functioning and 
social functioning in asthma patients compared to controls [152]. 
1.19.2 Impact of atopic disease on health-related costs 
The World Allergy Organization (WAO) have made a report (WAO White Book on Allergy) 
updated in 2013 and summarizing the burden of allergic diseases worldwide, referred in an 
editorial article by Pawankar [153]. According to WAO, 300 million patients have asthma and 
it is expected to increase to 400 million, by 2025 [153]. Direct and indirect costs are high 
(Table 1), in particular in severe or uncontrolled asthma. Paediatric asthma results in 14 
million missed days of school each year in USA and high numbers of lost workdays for care-
givers. An increase of asthma in children in lower-income countries, will lead to long-term 
consequences for their education and perpetuation of their poverty. The costs for treating 
rhinitis in the USA have doubled in 5 years to 11 billion US$ in 2005. In the developed 
countries, the financial burden of asthma ranges from US$ 300 to 1300 per patient per year 
annually. In developing countries, like Vietnam it is estimated to be US$184 per patient per 
year and in India, the monthly cost of medication for an asthmatic child can amount to one 
third of an average family’s monthly income [153]. 
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Table 1. The economic burden of allergy – annual costs 
 
Country Year Population Disease Direct costs* Indirect costs** Total costs 
Australia 2007 23 million All allergies Aus$ 1.1 billion Aus$ 8.3 billion Aus$ 9.4 billion 
Finland 2005 5.3 million All allergies € 468 million € 51.7 million € 519.7 million 
South Korea 2005 50 million Asthma   US$ 1.78 billion 
South Korea 2005  Allergic 
rhinitis 
  US$ 226 million 
Israel  7.5 million Asthma   US$ 250 million 
Mexico 2007 103 million Asthma   US$ 35 million 
USA 2007 310.2 million Asthma US$ 14.7 billion US$ 5 billion US$ 19.7 billion 
USA 2005  Allergic 
rhinitis 
US$ 11.2 billion Up to US$ 9.7 
billion 
Up to US$ 20.9 
billion 
 
A few global facts and figures for two common allergic diseases: asthma and rhinitis. *Direct costs: Expenditure 
on medications and health care provision. **Indirect costs: Cost to society from loss of work, social support, loss 




1.20 Study research questions and hypotheses 
 
How frequent are allergic diseases and allergic sensitization in adolescents in the Arctic 
region of Norway (Tromsø and Balsfjord)? Are allergic diseases and sensitization to multiple 
allergens associated with S. aureus carriage or sensitization to staphylococcal enterotoxins? 
These research questions were addressed in a cross-sectional study; The Tromsø Study Fit 
Futures 2 (TFF2). We hypothesized that allergic diseases are common among adolescents in 
Tromsø and Balsfjord and that the prevalence would be similar to comparable countries in 
northern Europe. Furthermore, we hypothesized that allergic diseases and multiple allergen 
sensitizations are associated with S. aureus carriage and/or sensitization to staphylococcal 
enterotoxins. 
Can fish-allergic children and adolescents tolerate some fish species? How useful are specific 
IgE measurements to fish allergen extracts and molecules in the diagnosis of fish allergy and 
tolerance? What are the threshold doses for allergic reactions in fish allergy? These research 
questions were addressed in a DBPCFC-trial; The Tromsø Fish Allergy Study (TRO-FAST). 
We hypothesized that clinical cross-reactivity between cod, salmon, and mackerel is common 
in children and adolescents with fish allergy, but that tolerance to one or more species exists 
in a considerable proportion of the participants. We suspected that most participants would 
react to cod. Due to the homogeneity between parvalbumins of different species, we expected 
to find widespread cross-sensitization between fish allergen extracts and parvalbumins that 
would limit their utility in the diagnosis of clinical reactivity in fish allergy. Due to less cross-
sensitization between enolase and aldolase in different fish species, we hypothesized that sIgE 
to enolase and aldolase may add some information in the diagnostic work-up of fish allergy. 
Finally, we hypothesized that threshold doses for allergic reactions are lower for cod 




1.21 Aims of the thesis 
 
The overall aim of this thesis is to contribute to the understanding of the development of 
multiple allergic diseases and multiple allergies in children and adolescents in the Arctic 
region of Norway.  
My first aim was to gain novel insight in the epidemiology of allergic diseases in late 
adolescents and to investigate how allergic diseases and multiple allergen sensitizations are 
associated with S. aureus carriage and enterotoxin-sensitization, in order to expand our 
understanding of allergy development and multimorbidity. 
My second aim was to gain novel insight in cross-reactivity between different fish species in 
children and adolescents with allergy to multiple fish species, in order to improve diagnosis 
and management of fish allergy. 
The specific objectives were: 
 To describe prevalence`s of asthma, allergic rhinitis, atopic dermatitis and allergic 
multimorbidity in adolescents and compare with prevalence trends from national and 
international studies (Paper I).  
 To describe sensitization to common food and inhalant allergens and its association to 
allergic disease and compare with trends from national and international studies (Paper 
II).  
 To study associations between allergic diseases and nasal S. aureus carriage (Paper I) and 
between allergic diseases/allergic sensitization and staphylococcal enterotoxin 
sensitization (Paper II). 
 To assess cross-reactivity between cod, salmon and mackerel in fish allergic children and 
adolescents, and in particular describe the rate of participants who are tolerant to one or 
two of the three fish species tested (Paper III).  
 To assess the utility of specific IgE to fish extracts, parvalbumins, aldolases and enolases 
in the diagnostic work-up of fish allergy (Paper III) 
 To estimate threshold doses for subjective and objective allergic symptoms for cod, 




2 Material and Methods 
2.1 Samples 
The Tromsø Study Fit Futures (TFF) cohort was initiated in 2010-11. All first-year high 
school students in both academic and vocational educational programs from all eight high 
schools in the municipalities of Tromsø and Balsfjord were invited to participate (TFF1) and 
92.8 % attended [154]. In this region, more than 90% of the population in the age group 16-19 
years attend high school. In the second wave of the study (2012-13), all third-year high school 
students, including all participants from TFF1, were invited for follow up (TFF2). Among 
1208 invited students 868 (71.9%) participated in TFF2. ”Atopic disease in adolescents in 
Northern Norway”, is one of 17 study projects in TFF2.  It is a population based cross-
sectional study. 
Each participant completed a web-based general health and lifestyle questionnaire 
(http://www.questback.com) and underwent clinical examination during a 1-day session, 
between November 2012 and June 2013. Among the 868 participants, 844 (97.2 %) answered 
the questionnaire. A total of 825 (95.1%) underwent clinical examinations, 812 (93.5 %) 
measured fractional exhaled nitric oxide (FeNO) and 804 (92.6 %) performed spirometry with 
reversibility test. Another 819 (94.4%) participants had a nasal swab done for analysis of S. 
aureus colonization. Moreover, samples for identification of S. aureus were successfully 
taken from eczematous skin in 46 of 63 participants with eczema on the day of visit.  
 
Figure 3. Flow diagram with completed tests. Tromsø Study Fit Futures 2 
 
Invited to participate, n=1208 
• Did not attend, n=340 (28.1 %) 
Attended the study, n=868 (71.9%) 
•Answered the questionnaire: 825/868 (95.1 %) 
•Nasal swab for S. aureus carriage: 819/868 (94.4 %) 
•Exhaled nitric oxide (FeNO): 812/868 (93.5 %) 
•Blood sample for specific IgE to food and inhalant allergens: 765/868 (88.1 %) 
•Serum available for Staphylococcal Enterotoxin IgE: 656/868 (75.6%) 
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Tromsø Fish Allergy Study (TRO-FAST) is a cross-sectional diagnostic study on fish allergic 
children and adolescents recruited from outpatient clinics at the University Hospital of North 
Norway. The study was conducted at the Research Unit, University Hospital of North Norway 
between September 2014 and August 2015. Seventy-three children and adolescents, between 
5 to 20 years of age, with a clinical history of previous allergic reaction to fish and a positive 
sIgE/skin prick test to fish, were invited to participate. Forty-seven consented to participate. 
Three had outgrown their fish allergy, and 44 were enrolled in the study. Nine participants did 
not complete the study; eight due to problems with eating the test food and one due to 
migration out of Tromsø. One participant participated only in the open OFC. 
 




Invited to participate n = 73 
•Did not concent to participate, n= 26 
•Did not meet inclusion criteria, n=3 
Included, n=44 
•Excluded due to migration, n =1 
•Not able to perform DBPCFC, n = 8 
Completed, n = 35 
•DBPCFC, cod, salmon and mackerel, n=34 
•OFC with cod, n=14 
•OFC with salmon, n=31 
•OFC with mackerel, n=32 





The MeDALL (Mechanisms of the Development of Allergy) core questionnaire was used in 
both TFF2 and TRO-FAST to collect information about allergy, atopic dermatitis, asthma and 
risk factors [155]. The questionnaire was translated from Swedish to Norwegian and back 
translated in good agreement with the original Swedish and English versions. In TFF2, the 
adolescent version (appendix 9.1) was incorporated in a common web-based questionnaire for 
all studies in TFF2. In TRO-FAST, separate versions were used for parents (appendix 9.2) 
and adolescents (12-18 years) (appendix 9.1). 
2.2.2 Assessment of S. aureus carriage – nose and skin (TFF2) 
Both anterior nares were swabbed with a NaCl-moistened sterile rayon-tipped swab in 819 
participants and eczematous skin areas in 46 participants with active eczema. The eczematous 
skin was rubbed with a NaCl-moistened compress prior to swabbing.  S. aureus was identified 
using methods previously described [156] with a few modifications; all swabs were 
submerged into Bacto® m Staphylococcus medium broth (Difco laboratories, Sparks, MD, 
USA) for enrichment and incubated for 18-24 hours at 37 °C before plating. The liquid 
culture was then plated on blood agar (Oxoid, Cambridge, UK) and S. aureus ID agar (SAID, 
bioMérieux, Marcy I′Etoile, France), incubated for 18-24 hours at 37 °C. The most 
dominating colony was selected and confirmed as S. aureus by the Staphaurex Plus (Remel, 
Lenexa, KS, USA) agglutination test. Only observations of bacterial growth on blood agar 
(Oxoid, Cambridge, UK) and/or SAID agar (BioMérieux, Marcy I′Etoile, France) plates 
were included. We defined a positive S. aureus culture result as S. aureus carriage. We did 
not perform quantitative analysis of bacterial load.  
2.2.3 Lung function test (TFF2) 
Lung function was measured with spirometry with reversibility test using Easy on-PC 
(Medizintechnik AG, Zürich, Switzerland), according to guidelines from American Thoracic 
Society/European Respiratory Society (ATS/ERS) [157]. The best result of three approved 
tests was used. Reversibility was tested using 0.2 mg Salbutamol inhalation aerosol as 
bronchodilator (Airomir Autohaler® 0.1 mg/dose, 0.2 mg x 1, Teva Norge AS/IVAX Norge 
NUF). Post-bronchodilator spirometry was performed 15-25 min after inhalation of 
salbutamol. Pre- and post salbutamol values for forced vital capacity (FVC), forced expiratory 
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volume the first second (FEV1) and FEV1/FVC were recorded and expressed as % predicted 
according to reference values. The Global Lungs Initiative (GLI 2012) equations were used as 
reference for spirometry [158]. Spirometry data were anonymized at analysis.  
2.2.4 Exhaled nitric oxide (TFF2) 
Fractional exhaled nitric oxide (FENO) was measured with one measurement in every 
participant using NIOX MINO® (Aerocrine AB, Solna, Sweden). All measurements were 
performed before performing spirometry [159-161].  
2.2.5 Serum sIgE (TFF2 and TRO-FAST) 
Specific IgE were measured both in TFF2 and TRO-FAST with three mixes of allergens; rx6, 
containing extracts from birch, timothy, mugwort, alternaria and cladosporium, rx7 
containing extracts from cat, horse, dog, house dust mite, and rabbit and fx5 containing 
extracts from egg white, milk, cod, peanut, wheat, and soy (ImmunoCAP, Phadia-
Thermofisher, Uppsala, Sweden). To assess number of allergen sensitizations in TFF2 we 
divided participants, separately for inhalant and food allergens, in non-sensitized, mono-
sensitized (1 allergen), and poly-sensitized groups (>1 allergen) [162]. To assess the total 
levels of specific IgE values in TFF2, all values from either food or inhalant allergens were 
added and reported as median sum of inhalant or food allergen values with 95 % confidence 
intervals. In addition, IgE against SE-A, SE-B, SE-C and TSST (Toxic Shock Syndrome 
Toxin) were analysed in TFF2 in spring 2016 in serum samples stored at minus 70°C.  
Specific IgE values < 0.35 kUA/L for a screening panels (rx6, rx7 and fx5) were interpreted as 
negative for all included allergens. If screening panels had IgE ≥ 0.35 kUA/L, then specific 
IgE was measured to all allergens included in the screening panel. In line with previous 
publications, a lower cut-off level for SE-sensitization, IgE > 0.1 kUA/L, was chosen [35, 49, 
50, 54]. In TFF2, all serum analyses were performed at the Department of Laboratory 
Medicine, University Hospital of North Norway. Specific IgE to cod, salmon and mackerel 
allergen extracts were determined by ImmunoCAP (Phadia-Thermofisher, Uppsala, Sweden). 
Sensitization was defined by sIgE > 0.10 kUA/L. sIgE to the fish-allergen molecules 
parvalbumin, enolase and aldolase from cod, salmon and mackerel were determined at the 
Department of Infection and Immunity, Luxembourg Institute of Health, using enzyme linked 
immunosorbent assays, as previously reported [84]. Parvalbumins, enolases and aldolases 
from the three fish species were purified by column chromatography to homogeneity followed 
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by purity and identity check [84], and classified according to the International Union of 
Immunological Societies [136].  
2.2.6 Patient Oriented Eczema Measure (POEM score, TFF2) 
For monitoring disease severity of atopic dermatitis the Patient-Oriented-Eczema-Measure 
(POEM, appendix 9.3) was used in participants with ongoing eczema. It is a practical self-
assessed measurement tool for monitoring aspects of atopic dermatitis that are important to 
patients in routine clinical practice or in the clinical trial setting [163].  
2.2.7 Outcome definitions (TFF2) 
The classification of allergic diseases was based on the standardized self-reported questions 
(MeDALL) used by European population-based birth cohort studies on asthma and allergy, 
and validated in the International Study of Asthma and Allergies in Childhood (ISAAC) 























Table 2. Clinical outcome definitions, The Tromsø Study Fit Futures 2. 
 
 
2.2.8 Double-blind, placebo-controlled food challenge (TRO-FAST) 
Double blind, placebo-controlled food challenges (DBPCFC) with cod, salmon, mackerel and 
placebo were performed according to guidelines from the European Academy of Allergy and 
Clinical Immunology (EAACI) [94]. A low-dose protocol with standardized test-food 
developed for multicenter studies was used to examine allergic reactions to low doses of 
allergen [164]. Test-food for DBPCFC was developed in cooperation with the National Food 
Research Institute in Norway (Nofima) and the Molecular Allergology Group, Manchester 
Institute of Biotechnology, UK. Nofima made dried powders from cooked, boned and skinned 
cod, salmon and mackerel filets, measured protein content and examined for microbiological 
contamination. The Molecular Allergology Group made chocolate dessert matrixes containing 
the dried fish powders and placebo based on a recipe used in EuroPrevall studies on food 




Dry skin, itchy rashes with age-
specific location (antecubital or 
popliteal fossae, wrists, ankles, 
neck or face) for 2 weeks or more 
in the past 12 months, or self-
reported  atopic dermatitis  
combined with us of topical corti-
costeroids in the past 12 months 
(4). 
Current  atopic 
dermatitis or self-
reported doctor-
diagnosed  atopic 
dermatitis ever.  
 
Current atopic dermatitis and duration 
more than 1 month last 12 months or kept 
awake due to itchy rash during nights 
Asthma At least two of the following 3 
criteria: 1) self-reported doctor-
diagnosed asthma ever, 2) any 
indicative symptom in the last 12 
months (wheezing, shortness of 
breath, dry cough at night) and 3) 
use of asthma medication in the 
past 12 months (3). 
Current asthma or self-
reported doctor-
diagnosed asthma ever 
Current asthma and FENO >25 ppb or 
breathing difficulties last 12 months graded 
7-10 on a scale from 0 (no complaints) to 
10 (the hardest to imagine) and more than 
12 attacks with wheeze/breathing 
difficulties last 12 months. 
Allergic 
Rhinitis  
Symptoms of sneezing, a runny or 
blocked nose, or itchy, red and 
watery eyes after exposure to 
furred pets or pollen the last 12 
months (4). 
 




Current allergic rhinitis and use of nose 
spray last 12 months or nose symptoms 
more than 4 weeks in a row last 12 months 
or nose complaints graded 7-10 on a scale 
from 0 (no complaints) to 10 (the hardest to 
imagine) or having to stop activity due to 




Having at least two of the diseases 
current atopic dermatitis, current 




or at least two of self-
reported doctor-
diagnosed atopic 
dermatitis or asthma or 




allergy [164]. Chocolate dessert matrixes were stored frozen at -20°C, thawed and 
reconstituted with bottled water with additive of sugar and rum flavour 24 hours before use. 
Reconstituted desserts were stored in refrigerator at 4°C. 
Participants underwent four separate challenge days in randomized order, with at least 6 
weeks between each challenge day. Trained study nurses, blinded to the test food, recorded 
subjective and objective allergic symptoms based on previous published approaches [165]. 
The participants graded subjective symptoms of allergic reaction on a Visual Analogue Scale 
(VAS). A research nurse blinded to the content of the test food graded objective signs of 
allergic reactions from 0-3. One paediatric allergist (Martin Sørensen), blinded to the test 
food, classified all DBPCFC as negative, positive with objective symptoms or positive with 
subjective symptoms only. DBPCFC was stopped and classified as positive when predefined 
stop criteria were reached. Allergic reactions were treated according to EAACI guidelines for 
Food allergy and anaphylaxis [117]. Escalating doses of fish protein given in the DBPCFC 
were; 3 µg, 600 µg, 12.5 mg, 120 mg and 1 g. The cumulative dose of 1.13 g fish protein 
corresponds to about 5 g fish filet.  
2.2.9 Open oral food challenge (TRO-FAST) 
Participants with negative DBPCFC, or positive DBPCFC only with subjective symptoms, 
were tested with higher doses of the same fish species in open OFC. Fish burgers for open 
provocations were produced from minced filets from cod, salmon or mackerel filets, potato 
flour, water, salt and pepper. Fish burgers of 60 gram were oven baked at 90°C for ten 
minutes, vacuum packed and frozen at -20°C. They were served after being thawed over night 
at 4°C and heated in vacuum packing for 3 min in water with 80°C. Participants could choose 
to eat the fish burgers together with tomato ketchup. Nofima measured the protein content of 
the burgers. Open challenges were given with doses of 2 g, 6 g and 12 g of protein which 
correspond to a cumulative dose of approximately 100 g fish filet. Challenges were 
performed, symptoms and signs recorded and allergic reactions treated with the same 
procedures as for DBPCFC. The same paediatric allergist (MS), again blinded to the test food, 
classified all challenges as negative, positive with objective symptoms or positive with 
subjective symptoms only. The participants were not told which fish species they were 




2.3 Statistical analyses 
We performed statistical analyses with IBM SPSS® statistics, version 23. The characteristics 
of the study participants and the prevalence of symptoms of allergic diseases were described 
with summary statistics. Pearson's chi-square test was used in comparisons of categorical 
variables and Student’s t-test (normally distributed data) and Mann-Whitney U test (non-
normally distributed data) were used for comparisons of continuous variables. Multivariable 
logistic regression models were used to analyse associations between S. aureus carriage or SE 
sensitization with allergic disease. Separate analyses were performed with each allergic entity 
as dependent variable and with S. aureus carriage or staphylococcal enterotoxin (SE)-
sensitization as independent variables, adjusting for gender, body mass index (BMI), 
smoking, use of snuff tobacco and physical activity. Comparison between S. aureus carriage 
or SE-sensitization with food and inhalant allergen sensitization were performed with 
multinomial logistic regression models, comparing poly-sensitized or mono-sensitized groups 
with the non-sensitized group as reference category. A two-way between-groups analysis of 
variance was conducted to explore effect modification of SE-sensitization on S. aureus 
carriage. Statistical significance was assumed at a 5% level. Receiver operating characteristic 
(ROC) curves were used to analyse the performance of fish-allergen sIgE to discriminate 
between partially tolerant and non-tolerant participants. To estimate threshold doses, data 
were analysed using an interval censoring survival analysis approach [112]. Dose intervals 
were arranged from low to high doses by ordering lower and upper bounds of the intervals, 
and the step intervals were calculated according to the expectation-maximization algorithm. 
Dose distributions for objective and subjective reactions to each fish species were fitted by 
log-normal, log-logistic and Weibull distribution functions using Maximum Likelihood 
Estimation. As the three distributions were comparable in goodness of fit, the log-normal 
distribution was used to estimate the eliciting dose predicted to provoke an allergic reaction in 
10% of individuals with fish allergy (ED10). Confidence bands for the fitted distribution 
functions, and 95% confidence intervals of the ED10 values, were calculated by bootstrapping 
(1,000 resamples). The analyses were conducted with the statistical software R using the 




2.1 Ethical approval and trial registration 
The Regional Committee for Medical and Health Research Ethics approved TFF2: REK 
2012/1350, and TRO-FAST: REK 2013/757. All participants and parents (if participants were 
less than 16 years of age) signed informed consent.  




3 Summary of results 
Paper I and II. 
We found asthma (10.4%), atopic dermatitis (11.9%) and allergic rhinitis (26.0%) to be very 
common diseases among adolescents in Tromsø and Balsfjord. Asthma (55%) and atopic 
dermatitis (57%) were more common in conjunction with other allergic diseases than 
occurring as single entities. In contrast, allergic rhinitis (62%) more frequently occurred as a 
single entity. At least one of asthma, atopic dermatitis or allergic rhinitis were found in 36.5% 
of the participants, whereas 45.1 % had experienced at least one of these allergic diseases 
during their lifetime. Allergic multimorbidity, defined as more than one of these diseases was 
found in 10.2 % of the participants, more prevalent in women (12.7%) compared to men 
(7.9%), p=0.024. Atopic dermatitis was also more common among women (14.0 % vs 6.8%), 
p=0.001. Among participants with asthma (N=85) we found reduced lung function and 
increased FeNO in 11.6% and 22.1%, respectively. 
More allergy were reported and more participants were sensitized to inhalant allergens 
compared to food allergens. For all allergens, sensitization was considerable more frequent 
than reported allergic symptoms. We found specific IgE reactivity to at least one food or 
inhalant allergen in 319/765 (41.7 %) participants, more frequently in men (47.7 %) than in 
women (36.7 %),  p=0.003. Specific IgE reactivity to at least one allergen was found in 54/85 
(63.5%) participants with asthma, 48/79 (60.8%) participants with atopic dermatitis, 149/189 
(78.8%) participants with allergic rhinitis and 66/75 (88%) participants with allergic 
multimorbidity. 
 Nasal S. aureus carriage was found in 420/819 (51.3%) of the participants, with no gender 
difference, and was twice as prevalent as sensitization to at least one SE 173/656 (26.4%). Of 
173 SE-sensitized participants, 102 (59.0%) were sensitized to one SE, 36 (20.8%) to two 
SEs, 19 (11.0%) to three SEs and 16 (9.2%) to all four SEs. There was no statistically 
significant association between S. aureus carriage and SE-sensitization (p=0.062), and 56 % 
of SE-sensitized participants were current nasal S. aureus carriers. 
Nasal S. aureus carriage was associated with atopic dermatitis (OR 1.79, 95% CI 1.11-2.89), 
but not asthma and allergic rhinitis, in multivariable logistic regression models. S. aureus 
carriage was also associated with severe atopic dermatitis (OR 2.40, 95% CI 1.25-4.58), 
severe asthma (OR 3.37, 95% CI 1.34-8.51), severe allergic rhinitis (OR 1.70, 95% CI 1.09-
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2.66) and allergic multimorbidity (OR 1.64, 95% CI 1.02-2.64). After stratification, SE-
sensitization was only associated with allergic multimorbidity (OR 2.34, 95% CI 1.37-4.0).  
S. aureus carriage was more frequent in participants with polysensitization to inhalant 
allergens (OR 1.65, 95% CI; 1.19-2.31) compared to non-sensitized participants, but the 
difference was not statistically significant when SE-sensitized participants were excluded 
from the analysis. There was no difference between S. aureus carriers and non-carriers in 
sensitization to food allergens. 
Sensitization to SEs was more frequent in participants with polysensitization to food and 
inhalant allergens, compared to non-sensitized participants. The largest difference between 
polysensitized and non-sensitized was seen for SE-A; inhalant allergens (OR 7.89, 95% CI 
3.97-15.65) and food allergens (OR 16.76, 95% CI 7.77-36.14). In contrast, there was no 
difference between monosensitized and non-sensitized to inhalant allergens. The strongest 
association was seen in participants sensitized to all four SEs with OR 50.5 (95% CI 6.6-
389.3) for polysensitization to inhalant allergens compared with non-sensitization. 
Among participants with inhalant allergen sensitization, participants sensitized to at least one 
SE had significantly higher median sum of specific IgE values to inhalant allergens (41.4 
kUA/L, IQR 10.1-118.4) compared to non SE-sensitized participants (18.0 kUA/L, IQR 5.5-
48.6), p=0.004. In contrast, no statistically significant difference was seen between S. aureus 
carriers (22.1 kUA/L, IQR 5.7-53.3) and non-carriers (16.4 kUA/L, IQR 5.1-48.3), p=0.104, 
and when SE-sensitized participants were excluded from the analysis the p-values were 
almost identical (14.8 kUA/L vs 14.3 kUA/L), p=0.893. Moreover, there were no differences in 
median sum of IgE values to food allergens between SE-sensitized and non SE-sensitized 
participants (2.33 kUA/L vs 1.30 kUA/L), p=0.166, or between S. aureus carriers and non-
carriers (1.5 kUA/L vs 1.7 kUA/L), p=0.529. 
Overall, SE-sensitized participants had higher median total IgE levels (113.0 kUA/L, IQR 
42.0-116.3) compared to non-sensitized participants (24.1 kUA/L, IQR 9.2-60.0), p <0.001. 
However, no difference was seen between S. aureus carriers (34.5 kUA/L, IQR13.0-116.3) 





The mean (SD) age among the 35 participants (22 boys) who completed the study was 11.6 
(3.0) years. Around 2/3 of the participants had also asthma, atopic dermatitis and/or allergic 
rhinitis, and 31/35 (89%) had also other food allergies than fish allergy. 
 Any allergic symptoms were observed/reported from 33 (cod), 28 (salmon) and 28 
(mackerel) participants, whereas objective symptoms were observed in 32 (cod), 23 (salmon) 
and 19 (mackerel) participants. Five participants reported mild, transient subjective symptoms 
on placebo challenge, but had unequivocal findings during the DBPCFC-active arm and are 
thus included in the analysis. 
We found tolerance to at least one of three fish species (defined as partially tolerant) in 10 
(29%) participants regarding any symptoms and in 19 (54%) regarding objective symptoms. 
There was no difference between non-tolerant (reacting to all three fish species), and partially 
tolerant participants regarding age, sex, other allergies, parental allergy, asthma or atopic 
dermatitis.  
Oral itching and swellings/blisters were the most frequent subjective and objective symptoms, 
respectively, followed by itching and erythema/urticaria of the skin. Involvement of more 
than one organ was seen in 14/35 participants. Upon challenge, two participants received 
adrenaline, but none had severe anaphylaxis requiring further observation or treatment.  
Sensitization to all three fish-allergen extracts and parvalbumins was found in nearly all 
participants, including participants without clinical reactivity, whereas sensitization to 
enolases/aldolases was predominantly found in participants with objective symptoms. 
However, many participants with objective symptoms were not sensitized to the 
corresponding enolase/aldolase. 
Non-tolerant participants had higher sIgE levels to fish-allergen extracts and parvalbumins 






Table 3. Median sIgE in partially tolerant vs non-tolerant participants regarding objective and 
subjective symptoms. 
 
Comparison of sIgE (kUA/L) between groups are performed with Mann Whitney U test.  
Partially tolerant: No symptoms to at least one fish species (cod, salmon or mackerel).  
Non-tolerant: Symptoms to all three of cod, salmon and mackerel.  
*All participants with subjective symptoms, including participants with objective symptoms.  
Significant differences in bold. One participant did not show any allergic reaction during fish challenge, and is 
































Cod  Extract sIgE  8.8 (1.6-18.9) 19.5 (6.0-49.3) 0.064 4.0 (1.1-13.2) 15.0 (6.0-36.0) 0.017 
Cod Parvalbumin 
sIgE (Gad m 1) 
8.0 (1.5-20.6) 13.4 (5.5-41.1) 0.103 5.1 (0.7-13.6) 12.5 (5.5-36.9) 0.034 
Cod Enolase sIgE   
(Gad m2) 
0.8 (0.3-1.4) 0.9 (0.1-1.6) 0.792 0.4 (0.3-1.2) 0.9 (0.1-1.6) 0.478 
Cod Aldolase sIgE   
(Gad m 3) 
0.4 (0.1-1.5) 1.3 (0.1-1.8) 0.217 0.4 (0.1-0.9) 1.2 (0.1-1.8) 0.144 
Salmon Extract IgE  4.7 (0.9-13.1) 13.5 (6.7-23.6) 0.052 1.8 (0.4-6.8) 12.2 (5.7-25.3) 0.003 
Salmon 
Parvalbumin IgE 
(Sal s 1) 
4.7 (2.3-12.1) 12.4 (4.9-30.3) 0.052 4.5 (1.2-11.1) 11.2 (2.7-26.6) 0.085 
Salmon Enolase sIgE 
(Sal s 2) 
0.1 (0.1-0.1) 0.1 (0.1-0.4) 0.076 0.1 (0.1-0.1) 0.1 (0.1-0.1) 0.125 
Salmon Aldolase 
sIgE (Sal s 3) 
0.1 (0.1-0.1) 0.7 (0.1-2.1) 0.015 0.1 (0.1-0.4) 0.1 (0.1-1.4) 0.288 
Mackerel Extract 
sIgE  
2.1 (0.4-4.7) 5.5 (1.7-9.7) 0.026 0.6 (0.1-2.4) 5.4 (1.8-9.6) 0.002 
Mackerel 
Parvalbumin sIgE 
(Sco s 1) 
3.4 (1.9-13.4) 13.1 (5.6-49.2) 0.029 3.1 (1.1-9.3) 12.9 (2.7-26.3) 0.039 
Mackerel Enolase 
sIgE (Sco s 2) 
0.1 (0.1-0.1) 0.1 (0.1-0.1) 0.922 0.1 (0.1-0.1) 0.1 (0.1-0.3) 0.273 
Mackerel Aldolase 
sIgE (Sco s 3) 
0.1 (0.1-0.1) 0.1 (0.1-0.1) 0.853 0.1 (0.1-0.1) 0.1 (0.1-0.1) 0.813 
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Specific IgE to extracts discriminated best between the non-tolerant and partially tolerant 
groups. sIgE to cod extract >8.2 kUA/L or salmon extract >5.0 kUA/L identified 18/24 and 
19/24 non-tolerant participants, respectively, whereas below these cut-off values, 8/10 and 
9/10 partially tolerant participants were identified.  
Finally, we estimated the eliciting dose predicted to provoke an allergic reaction in 10% of 
individuals (ED10), based on dose distribution curves (Figure 5).  
Figure 5. Dose-distribution curves and ED
10
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We found ED10 for cod protein in line with previously published data [112]. ED10 was lowest 
for cod and highest for mackerel, but the low number of participants with objective reactions 
to salmon and mackerel reduces reliability of these estimates. However, comparison of lowest 
observed adverse effect levels (LOAEL) for objective symptoms to cod, salmon and mackerel  
shows more participants with low LOAELs for cod compared to salmon and mackerel.   
ED
10 
= 42.9 mg  (95% CI; 11.2-138.9) 
ED
10 




4.1 Discussion of results 
In this thesis, we have studied important issues as epidemiology, aetiology, cross-
sensitization, cross-reactivity and diagnostic work-up in the field of allergic disease in 
children and adolescents, with special attention to the development of multiple allergies. We 
found allergic disease to be common among adolescents in the Arctic region of Norway and 
in line with comparable countries in northern Europe. We found atopic dermatitis and severe 
asthma, severe allergic rhinitis and allergic multimorbidity to be associated with nasal S. 
aureus carriage, whereas SE-sensitization was associated to polysensitization to food- and 
inhalant allergens and allergic multimorbidity. Cross-sensitization and cross-reactivity to 
multiple fish species were common among children and adolescents with fish allergy, but 
around one third could tolerate at least one fish species without any reactions and around half 
could tolerate at least one fish species without objective reactions. IgE measurements to fish 
allergen extracts and molecules cannot substitute oral food challenges in the diagnosis of fish 
allergy and tolerance, but combined use of clinical history and IgE measurements may reduce 
the number of challenges needed for a precise diagnosis. Finally, threshold doses for eliciting 
allergic reactions seem to be lower for cod, compared to salmon and mackerel.  
Compared to the Swedish BAMSE study [166] , the British IOW study [167]  and the German 
MAS study [15], the prevalence of allergic disease in our population is close to the findings in 
Sweden and Germany, except for asthma, which is lower in Sweden. In the UK, there are 
higher prevalence for asthma, allergic rhinitis and multimorbidity [167]. The prevalence of 
sensitization to at least one food or inhalant allergen in our study is in line with  findings from 
the UK [167], but slightly lower than reported for 16 year old adolescents in Southern 
Norway [168] and Sweden [166]. Allergenic exposure in the Arctic region is probably quite 
similar to Sweden, Germany and UK.  
We found a female predominance of atopic dermatitis and multimorbidity. It has been 
hypothesized that sex hormones play a role in the pathogenesis of allergic diseases [169, 170]. 
Androgens appear to have immunosuppressive effects while oestrogens are pro-inflammatory 
and may increase the susceptibility to atopy. Influence of sex hormones may thus explain the 
gender difference in our results. 
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S. aureus carriage was twice as common as sensitization to SE. This may partially be due to 
carriage of S. aureus strains not producing enterotoxins and partially due to SE-sensitized 
participants no longer being S. aureus carriers. In adults, only on fourth had nasal S. aureus 
carriage in a previous population based study from the same region [156]. The reason for 
strikingly higher nasal S. aureus carriage among adolescents is not clear.  
Both S. aureus carriage and SE-sensitization have previously been shown to be associated 
with allergic disease [42, 44-47, 49-55]. Our results indicates that S. aureus carriage may 
influence the severity of allergic diseases, whereas SE-sensitization may influence on poly-
sensitization to food and inhalant allergens. Both S. aureus carriage and SE-sensitization were 
associated to allergic multimorbidity.   
In line with a study among adult patients with allergic rhinitis, we found no association 
between S. aureus carriage and poly-sensitization to food and inhalant allergens [45]. In 
contrast to our findings, among the adult patients with allergic rhinitis, poly-sensitization was 
not associated with sensitization to SE-A and SE-B, using a higher cut-off for sIgE (0.35 
kUA/L) than we did (0.10 kUA/L) [45]. This difference may partly be due to the difference in 
cut-off values for SE-sensitization but also due to more enterotoxins tested in our study. We 
found higher sIgE levels to inhalant allergens in SE-sensitized participants compared to 
participants not sensitized to SE, whereas no association was found for food allergens. No 
association was found between S. aureus carriage and level of sIgE food or inhalant allergens. 
In addition, SE-sensitization, but not S. aureus carriage, was strongly associated to the level 
of total IgE. 
In contrast to many studies, we found no association between SE-sensitization and asthma or 
allergic rhinitis. However, the statistically non-significant effect estimates (i.e. odds ratios) in 
our study are comparable to the effect estimates in other studies. This indicates that our 
findings may be in line with other studies, but due to smaller sample size, the differences in 
our study are non-significant. In the German MAS study, a moderate relationship between 
SE-sensitization and asthma was found at age 20, but not after adjusting for potential 
confounders. In a GA
2
LEN study on adult patients, SE-sensitization was associated with 
asthma in the general population [49, 50]. Stronger associations to SE-sensitization have been 
shown for adult [35] and elderly [54] patients with asthma and severe asthma, indicating that 
the influence of SE may increase with age. In asthmatic patients, SE-sensitization is 
commonly detected in patients with severe asthma [49, 51]. In contrast, in a recent Brazilian 
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cross-sectional study on asthma patients there was no difference in SE-sensitization between 
patients with mild and severe asthma [171]. In this Brazilian study, 43.7% of asthma patients 
were sensitized to SE, but they did not include healthy controls for comparison. 
In our study, both S. aureus carriage and SE-sensitization are strongly associated with an 
increase in FeNO > 25 ppb. Thus, both may influence the pathogenesis and severity of 
allergic sensitization and disease. Possibly, S. aureus carriage may induce inflammation 
through other pathways than SE-sensitization, which may explain the associations to severe 
allergic diseases and other airway diseases such as chronic rhinosinusitis. A link has been 
shown between S. aureus biofilms and skewing of the T-cell response toward the Type 2 
pathway that is independent of superantigen activities [172]. It is possible that S. aureus can 
induce release of epithelial derived cytokines that may contribute to the inflammation. 
The role of S. aureus skin carriage contributing to the exacerbation of atopic dermatitis is well 
established [43, 173-175], and SE sensitization is also shown to be strongly associated with 
atopic dermatitis [176-178]. The majority of participants colonized with S. aureus on 
eczematous skin were also colonized in the nose, pointing to the nose as the source of S. 
aureus in patients with atopic dermatitis. In our study, the role of S. aureus carriage in atopic 
dermatitis exacerbation was supported by increasing eczematous skin carriage rates with 
increasing atopic dermatitis severity, as previously reported in other studies [175, 179].  
Finally, our study supports the MeDALL hypothesis, suggesting that S. aureus may induce re-
occurrence of foetal type 2 signalling, resulting in polyclonal allergen sensitization and 
allergic multimorbidity [146]. It is possible that the activation of Type 2 immune responses by 
S. aureus leads to the re-occurrence of Type 2 foetal pathways. Type 2 immunity is involved 
in IgE production, polyclonal activation, the cellular inflammation of atopic dermatitis, 
asthma and allergic rhinitis [180] as well as in the regulation of the epithelial barrier function 
in the skin [181], the airways [182] and Type 2 responses [183]. S. aureus can induce sIgE 
class switching in nasal polyps [184]. IL-33 may be of great importance in the understanding 
of multimorbidity and poly-sensitization [185] as it modulates the expression of human β-
defensin 2 in human primary keratinocytes and may influence the susceptibility to bacterial 
superinfection in acute atopic dermatitis.  
Our epidemiological data does not prove causation and the observed associations could also 
be the result of reverse causation; inflammation due to allergic disease makes the mucosa 
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more susceptible to S. aureus carriage. Many studies suggest that S. aureus carriage play a 
role in the severity of established allergic diseases. This is supported by our findings, but 
pathophysiological mechanisms and putative therapeutic or prophylactic consequences need 
to be addressed in future studies.  
Spirometry showed signs of current obstruction in 11.6% of asthmatic participants, and only 
around 5% showed reversibility after inhalation of salbutamol. Spirometry has a low 
sensitivity to diagnose asthma [186, 187]. This may be due to the intermittent course of 
asthma and good asthma control in treated patients. In line with others [160], we also found 
that only one fifth of asthmatic participants had increased levels of FeNO > 25 ppb.  
Furthermore, in a Norwegian study on adolescents with bronchiolitis in infancy, exhaled 
nitric oxide was related to atopy, but not to asthma [188]. Some international guidelines 
recommend using FeNO in phenotyping airway inflammation and monitoring of severe 
asthma [160] while recent international guidelines on severe asthma suggest that clinicians 
should not use FeNO to guide therapy in adults or children [189]. We found that FeNO > 25 
ppb was associated to asthma only in participants with nasal S. aureus carriage. A possible 
explanation for this finding is nasal eosinophilic inflammation due to staphylococcal 
superantigens. 
In line with our hypothesis, clinical experience and previous small studies, we found a high 
degree of clinical cross-reactivity between fish species in fish allergic children and 
adolescents. However, more than half of all participants had objective tolerance, and around 
one third had subjective tolerance to at least one fish species. We also found that we could 
predict the outcome at challenge in the majority of patients by combining information from 
traditional fish allergen extracts and new fish allergen molecules.  
Two small studies from the last century compared clinical cross-reactivity between fish 
species using DBPCFC, both reporting higher frequency of partial tolerance compared to our 
study [75, 77]. In our study, reactions to cod were more serious and more prevalent and with 
lower threshold doses for reactions, compared to salmon and mackerel. This may be due to 
high consumption of cod and cod being the primary fish allergen sensitizer in our region.  
We found high rates of sIgE sensitization to cod, salmon and mackerel extracts and 
parvalbumins, in line with previous studies [68, 69, 190, 191]. More than 90% of  participants 
were sensitized to all three parvalbumins, a higher proportion than in a recent European study 
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[84]. The ability of fish allergen extracts and parvalbumins to identify tolerance to specific 
fish species in fish allergic patients was poor. This may be due to cross-reacting parvalbumins 
[73, 80]. Sensitization to cod enolase/aldolase was more prevalent compared to salmon and 
mackerel enolase/aldolase. This finding may be due to less inter-species IgE cross-reactivity 
between enolases/aldolases, compared to parvalbumins [84], and cod being the primary cause 
of sensitization.  
We believe it is important to identify partial tolerance in order to avoid unnecessary food 
restrictions. At study entry, already three quarters of the participants avoided more than one 
food. Indeed, two of the invited patients were diagnosed with hypothyroidism due to iodine 
depletion, most probably caused by avoidance of iodine containing foods as fish and dairy 
products.  
We also believe it is desirable to substitute time-consuming food challenges, with risks of 
serious allergic reactions, with less invasive diagnostic procedures in diagnosing fish allergy. 
However, the specificity of sIgE extracts or parvalbumins in order to identify tolerance was 
low, as nearly all participants tolerant to salmon and mackerel were still sensitized. In 
contrast, participants with tolerance were not sensitized to enolase/aldolase to the respective 
fish species. However, many participants with confirmed allergy were not sensitized, in 
particular to salmon and mackerel enolase/aldolase. Useful in the diagnosing process of fish 
allergy is the finding that sensitization to enolase/aldolase most probably represents allergy 
with objective symptoms, and food challenge may be unnecessary. 
Furthermore, we analysed how these tests could discriminate between the non-tolerant and 
partially tolerant groups, irrespective to which fish species they were tolerant. We found that 
sIgE to salmon extract at a cut-off level around 5 kUA/L and cod extract at a cut-off level 
around 8 kUA/L, discriminated rather well between non-tolerant and partially tolerant 
participants. Using these cut-off values will identify around 75% of the non-tolerant patients. 
It would have been preferable to use lower cut-off values and identify more non-tolerant 
patients (i.e. 95%), but this would give more partially tolerant patients being classified as non-
tolerant.  Furthermore, there may be variable allergen levels in different allergen batches. 
Suggested cut-off levels based on allergen extracts therefore need cautious interpretation [80]. 
In our study, both children and adolescents were studied. IgE levels and cut-off values may 
differ between different age groups and give further uncertainty to the estimated cut-off 
values. Based on the above limitations, the estimated cut-off values have to be used with 
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caution.  Still, in a clinical setting, patients with an obvious history of self-reported fish 
allergy and salmon extract sIgE clearly above 5 kUA/L or cod extract above 8 kUA/L, may be 
advised to avoid all fish species, and food challenges seem unnecessary. The only risk with 
this approach is that a few patients with partial tolerance are advised to avoid all species of 
fish. Most participants with salmon sIgE ≤ 5 kUA/L and cod extract t sIgE ≤ 8 kUA/L tolerated 
at least one fish species. Some of these patients are non-tolerant, of which a proportion could 
avoid food challenge if confirmed sensitization to enolase and/or aldolase. In contrast, 
patients with sIgE < 0.1 kUA/L to enolase/aldolase may still have fish allergy and must 
undergo challenge with the respective species in order to identify or rule out partial tolerance. 
Thus, our results indicate that sIgE to enolase/aldolase may have a specific role in diagnosing 
or ruling out fish allergy when it comes to species such as cod, salmon and mackerel.  
Participants with only subjective symptoms did not report symptoms to placebo. However, 
many participants with only subjective symptoms had troublesome oro-allergic or abdominal 
subjective symptoms. Food challenges are usually rated positive only if objective reactions 
are observed [94]. Although the symptoms were not serious, the discomfort of the subjective 
symptoms restricted them from eating fish. Based on these observations, we consider 
participants with only subjective symptoms as fish allergic patients, but with a milder allergy 
phenotype compared to patients with objective symptoms. This is supported by no significant 
difference in IgE titres between participants with objective symptoms and only subjective 
symptoms. This is also in line with “A new framework for the documentation and 
interpretation of oral food challenges in population-based and clinical research” [192]. 
Previously published ED10 values for objective and subjective symptoms to cod are in line 
with our findings [112].  The estimated ED10 values for objective symptoms to salmon and 
mackerel were based on limited number of observations and have to be interpreted with 
caution. However, ED10 for subjective symptoms to salmon and mackerel were higher for 
salmon and highest for mackerel, compared to cod. Comparison of lowest observed adverse 
effect levels(LOAEL) for objective symptoms to cod, salmon and mackerel also shows more 
participants with low LOAELs to cod compared to salmon and mackerel, indicating that ED10 
is likely to be higher for salmon and mackerel. However, it will require additional challenges 
in salmon and mackerel allergic patients to confirm this. Another limitation of the estimated 
threshold doses is the variation in age among the participants. Threshold doses may vary with 
age, especially between younger children and adolescents. However, the small sample size 
restricted us from estimating threshold doses in subgroups of age. 
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Despite being the largest DBPCFC fish allergy study ever performed, the relatively low 
number of participants limits the power to detect small differences between groups. This is 
discussed in more detail in chapter 4.2.7.  In spite of these limitations, we still believe the data 
represent good estimates of the patterns of cross-reactivity and severity in the fish allergic 
population in the region of North Norway, but results may not be directly applicable to other 
regions with other food traditions and sensitization patterns. Furthermore, children of lower 
age had higher dropout rates due to poor palatability of the test food. None dropped out due to 
allergic reactions. A methodological limitation is that the production of test food for challenge 
involved thermal processing of the fish fillets, which reduces the allergenicity of many 
allergens. Cooking of fish marginally diminishes parvalbumin content and thus serological 
recognition, but may affect parvalbumins from various fish species differently [80, 190]. 
Thermal treatment may also reduce the allergenicity of enolase/aldolase [84, 193]. Other 
processing methods may either reduce or increase the allergenicity of parvalbumins [194].  
The main strength of our study is the randomized, placebo-controlled design using 
standardized test food, followed by open oral food challenge with higher doses of protein. Six 
weeks intervals between the challenges reduce the possibility of transient tolerability, 
possibly affecting the results of the next challenge. Furthermore, blinding of the participants 
and the paediatric allergist reduces biases known to occur in open food challenges. 
4.2 Methodological considerations 
4.2.1 Selection bias  
In TFF1, 92.8 % of the invited students attended the study, whereas 71.9% attended TFF2. 
Dropout from the study was partially due to migration, dropout from school and educational 
practice in other parts of Norway. This may have caused a selection bias in our sample. 
Dropout from school and education requiring practice periods are more common among 
students from low-income families with less education, which is associated with higher 
prevalence of many diseases. Thus, selection bias in our sample would most probably have 
underestimated the prevalence of allergic disease and sensitization. More participants were 
analysed for sIgE to food and inhalant allergens compared to SE because sIgE to SE was 
measured later in frozen stored sera and one box of the stored boxes with sera was missing. 
Thus, the difference in sIgE analyses is random and should not be a cause of selection bias. 
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The participants in TRO-FAST were recruited from outpatient clinics and may have more 
severe allergies compared to the total fish allergic population. This may lead to a selection 
bias with subsequent overestimation of the severity of fish allergy and underestimation of 
partial tolerance. In a recent EuroPrevall study in the Netherlands, there were large 
differences in self-reported food allergy between community and outpatients [195]. However, 
when selecting only those with a probable food allergy (i.e. symptoms of allergy and 
elevation of sIgE to the respective food), no major differences were observed with respect to 
severity, causative foods, sensitization and DBPCFC-results between community and 
outpatients. According to these results, choosing outpatient fish-allergic participants should 
not result in significant selection bias. 
There may also be difference in disease severity between those who consented to participate 
and those who not consented. Patients with the most severe reactions might not have 
consented because they were afraid of the reactions provocations with fish would elicit. On 
the other hand, they might have consented because they then had the opportunity to be tested 
in a safe setting in the hospital.  
Finally, there may be difference between dropouts and participants that completed the study. 
Eight of nine dropouts were among the youngest participants. They did not manage to eat the 
test food due to taste or volume. Compared with the total fish allergic population, our sample 
is therefore somewhat biased regarding age.  
We found no differences in sensitization to cod or salmon, age, sex or doctor diagnosed 
allergic diseases between participants and non-participants and age was the only characteristic 
that differed between dropouts and those who completed the study. Except from infants and 
small children, our sample should be representative for the fish allergic population of children 
and adolescents in our region. 
4.2.2 Questionnaire 
The MeDALL core questionnaire [155] for adolescents and parents is developed and 
validated by European experts in the field of asthma and allergy research. It is used in large 
European birth cohort studies, which makes comparison between studies and countries 
possible. Large questionnaires may lead parents and participants not to answer all questions 
with the same awareness. By giving time to answer the questionnaire between clinical 
examinations and measurements at the hospital, this kind of bias was minimized. Questions 
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about the past are prone to recall bias whereas recent history is easier to remember. In the 
MeDALL questionnaire, most questions focus on the past 12 months and the past week, 
thereby reducing this kind of bias. 
4.2.3  Outcome definitions 
There is lack of simple diagnostic tests with high sensitivity and specificity to diagnose 
asthma, atopic dermatitis and allergic rhinitis. The patient’s history is important, 
supplemented with clinical examination and other measurements. In research, the history is 
collected with questionnaires and outcome variables are constructed by combining variables 
from the questionnaire. However, operational definitions of asthma in recent epidemiological 
studies are inconsistent, even among studies based on the ISAAC questionnaire [196]. Using 
more or less strict outcome variables will either underestimate or overestimate the prevalence 
of the disease. When using six different outcome definitions of asthma used in different 
studies [197-202], all based on the ISAAC questionnaire, the prevalence of current asthma in 
our study varied from 6.2 % to 20.0%.  To obtain comparable prevalences with a European 
study of about the same size and with participants at the same age, we chose to use the same 
outcome definition for asthma as the German MAS study [15]. With this definition, the 
prevalence for asthma was 11.9%, whereas prevalence with the definition used in the Swedish 
BAMSE study was 10.7% [166]. For atopic dermatitis and allergic rhinitis, we used the same 
outcome variables as in the BAMSE study [166]. 
4.2.4 Spirometry with reversibility test 
Spirometry measures how an individual inhales or exhales volumes of air as a function of 
time [157]. With reversibility testing, a determination of airflow limitation is done by 
performing spirometry before and 15 min after administration of a bronchodilator. The 
spirometry test procedure is complicated and requires cooperation between the subject and the 
examiner. The quality of the obtained results depends on technical as well as personal factors 
with many possibilities for bias. Instruction by trained staff is especially important to reduce 
intra-observer variability, and a restricted number of instructors to reduce inter-observer 
variability. To reduce bias, one trained paediatric allergist, one trained assistant, or two 
trained study nurses performed all spirometry measurements in TFF2.  
In patients with asthma, spirometry between exacerbations may be normal and the sensitivity 
of the test may be low [203]. Reversibility test with bronchodilator or provocation with 
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exercise may increase sensitivity, but not sufficiently to be a good screening tool for asthma. 
Asthma diagnosis is based on the clinical history and the results of clinical examination and 
lung function tests. Even in children with severe asthma, reduction in lung function is an 
insensitive measure for identification of problematic severe asthma in unselected asthmatic 
patient populations [186]. In a recent study from our region, they found good agreement 
between the questionnaire responses and clinical assessments. The questionnaire had good 
validity and served as a useful epidemiological tool. Detailed clinical testing added little 
additional information [204].   
4.2.5 Serum specific IgE  
A good allergy test of low cost and low risk with high sensitivity and specificity is lacking. 
The patient history is important, and in some cases, enough to diagnose allergy. In food 
allergy, the performance of tests is often compared with the results from DBPCFC as the gold 
standard. Serum specific IgE is the most widely used laboratory test. It is measured in kUA/L 
as a continuous variable with a cut-off value often set to 0.35 kUA/L or 0.10 kUA/L. A 
positive test is interpreted as sensitization to that specific allergen. Sensitization is not the 
same as allergy and it is possible to be tolerant and sensitized to the same allergen. As a test 
of allergy, the specificity is low with many false positive tests. Studies use receiver operating 
characteristic (ROC) curves to find allergen specific cut-off values, to which allergy is present 
with 95% certainty. However, there are large variations between allergens and there is often 
no association between sIgE levels and seriousness of allergic reactions. The sensitivity of the 
test varies between different allergens, but is usually as high as 90-95% or even higher.  
Despite low specificity, sIgE is an important test in the diagnosis of allergy, and sensitization 
itself an important risk factor for allergic disease. In clinical practice, sensitization together 
with a clear history of allergic reactions is often enough to diagnose allergy. However, often 
the history is not clear, and the only way to confirm allergy or tolerance is to perform 
challenges. ROC curves for sIgE can be used to find the most optimal cut-off values for 
performing food challenges. 
An allergen source like fish, consist of many proteins of which only a few may act as 
allergens and elicit allergic reactions. With a conventional sIgE test, serum from the patient is 
exposed to an extract of many allergens (allergen extracts) and a positive test does not 
identify to which allergen(s) the patient is sensitized. The last 20 years, an increasing number 
of specific allergen molecules have been identified from many different allergen sources. 
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With component resolved diagnostics (CRD), each allergen molecule (highly purified 
proteins) can be tested separately for sensitization. Allergens may have different ability to 
elicit allergic reactions depending on the protein structure and the stability of the protein. For 
some allergies (e.g. peanut and hazelnut), CRD allows us to differentiate between primary 
sensitization and cross-sensitizations and to assess the seriousness of an allergy without 
performing challenges [205, 206]. Recently, sIgE to the peanut component Ara h2 in infants 
was shown to predict later peanut allergy in adolescents [207]. Increasing number of tests are 
available and routinely used in clinical practice. For fish, the only allergen molecule 
(component) available for clinical use is parvalbumin to cod and carp. Enolase and aldolase 
have been identified as important new fish allergens [84], and in our study they seem to have 
a role in confirming fish allergy in situations where the results from other fish allergens are 
unequivocal. 
4.2.6 Oral food challenges  
DBPCFC is the gold standard in diagnosing food allergy. The procedure is time-consuming 
with risk for serious allergic symptoms [94]. The suspected allergen is given in escalating 
doses and the patient is observed for allergic symptoms. If objective allergic symptoms 
evolve, the test is stopped and interpreted as positive. Standardized procedures performed by 
trained staff in a location equipped for immediate intensive care are essential. The test result 
may be biased due to inadequate test food or performance and interpretation of the test. Use 
of placebo is important because subjective symptoms may be due to psychological 
mechanisms. However, some patients may have a mild allergy with only subjective symptoms 
as itching in the mouth, mild stomach pain or nausea. If no symptoms on the placebo day, 
subjective symptoms on active substance are likely to represent an allergic reaction rather 
than psychological mechanisms. Although the observer is blinded, interpretation of the test 
may be biased. Objective symptoms may not be obvious if rashes or blisters are subtle. 
Standardized stop criteria are important. We used a grading system of symptoms used in other 
European studies; “DBPCFC – Clinical manifestations and grading” from the University 
Hospital of South Manchester, UK [165]. The participants VAS-graded subjective symptoms. 
DBPCFC was stopped when predefined stop criteria were reached or all doses completed. 
Stop criteria are also important for the safety of the participants. The observer dilemma is to 
continue the challenge until reliable objective signs are observed, but to stop the challenge 
before serious reactions evolve. Interpretation of symptoms is prone to bias due to both inter- 
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and intra-observer variability. In our study, we aimed to minimize bias by using only one 
trained paediatric allergist in the observations and interpretations of all challenges.  
In the DBPCFC test food, high volumes of dessert matrix were needed to disguise small doses 
of fish, resulting in a cumulative dose of fish protein of only 1.13 mg (equals approximately 5 
g fish filet). Participants with mild allergies may not react to this low dose. To avoid false 
negative tests due to low doses, all participants without symptoms or only subjective 
symptoms with DBPCFC, continued with open oral food challenges with higher doses of fish 
allergen after the randomization had been broken. 
Unfortunately, many of the youngest children did not like the dessert and refused to continue. 
However, by adding sugar and flavour, most children were able to complete the challenges. 
It has been questioned if DBPCFC may induce a transient tolerance to the tested allergen in 
allergic patients. If so, false negative DBPCFC could be the result of this effect. It is not 
known if this effect is present with fish allergens. To reduce or eliminate the effect of a 
potential transient tolerance induction, DBPCFC was performed with six weeks intervals 
between each challenge day. 
In summary, by using high quality test food in standardized test procedures, performed by 
trained staff and interpreted by one paediatric allergist, we believe bias due to DBPCFC was 
reduced to a minimum. 
To avoid false negative tests due to low doses, DBPCFC negative participants underwent 
open OFC with higher doses of fish protein. The result may be biased by psychological 
symptoms since there is no possibility to compare with placebo. The observer’s interpretation 
may be biased due to lack of blinding. To reduce bias, it is important to continue the test until 
objective signs of allergic reactions appear or top dose is reached. Open OFC was performed 
with fish burgers. To avoid confounding by other allergens, ingredients were restricted to 
water, potato flour, salt and pepper. Participants with no history of reaction to tomato were 
given the opportunity to use tomato ketchup. To maintain some blinding, participants were 
not told which fish species they were challenged with in the open challenges. Although fish 
burgers from cod, salmon and mackerel look different and have different taste, we expected 
that children having minimal experience with eating fish would not be able to identify which 
fish species the burgers contained. After completed challenge, participants were asked to 
guess which fish they had been challenged with. Participants correctly guessed which fish 
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species they had been served in the open OFC in the following ranking order mackerel (31%), 
cod (46%) and salmon (56%). Observer bias was reduced by blinding the paediatric allergist 
who examined the participants and interpreted the symptoms. 
Exposures other than fish allergens may influence the outcome of a challenge, by either 
confounding or interaction. Symptoms may be elicited, reinforced or reduced by non-allergic 
mechanisms. Controlling for these exposures can either be done by statistical methods or by 
eliminating the exposures. It is important to eliminate such exposures to reduce this type of 
bias. Some exposures may increase allergic symptoms and give serious reactions and harm 
for the participants. Thus, elimination of these exposures is necessary due to safety and ethical 
reasons. 
Several medications influence the outcome of oral food challenge, most of them by reducing 
allergic symptoms. To control for these effects, ongoing medication is registered and 
medication that influence symptoms have to be ceased for a predefined period before the food 
challenges (i.e. antihistamines have to be ceased at least 72 hours before the food challenge). 
Ongoing infections may increase the symptoms of an allergic reaction. All participants were 
examined before food challenges were started. If symptoms or signs of infections were 
present, the food challenges were postponed. Recent or ongoing allergic reactions make the 
interpretation of the food challenges impossible and may contribute to elicit more serious 
reactions. Participants were asked about recent allergic symptoms and examined for allergic 
signs before each food challenge. If symptoms or signs of allergic reactions were present, 
challenges were postponed. Pollen allergic patients were not challenged during the pollen 
season. It is also important that participants are not exposed to other allergens during 
challenge days. They were allowed to eat a light breakfast to which they knew they were 
tolerant. During the challenge, they were not allowed to eat other foods, but could drink water 
or lemonade. 
Co-morbidity with allergy and asthma is common and asthma is one of the most serious 
allergic symptoms in an allergic reaction. Uncontrolled asthma is a risk factor for 
anaphylactic reactions to an allergen. For safety reasons, it is of crucial importance that 
participants with asthma are well controlled before food challenges are performed. Before 
inclusion, all participants underwent a clinical examination, including auscultation of the 
lungs and lung function test with spirometry. Uncontrolled asthma was treated with 
adjustment of asthma medication. Before each food challenge, participants were asked about 
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asthma symptoms and examined with lung auscultation. If symptoms or signs of asthma were 
present, challenges were postponed and asthma treatment adjusted. Exercise may reinforce 
the effect of an allergen and even lead to anaphylaxis for some allergens (Exercised Induced 
Anaphylaxis). Participants were told not to do exercise before, during or after the food 
challenges on challenge days. 
4.2.7 Statistical methods including sample size 
We used multivariable logistic regression models to study associations between S. aureus 
carriage/SE-sensitization and allergic disease/allergic sensitization. These models are used to 
show statistical associations but cannot be used to prove causality. Furthermore, statistical 
associations may be biased by other variables not corrected for in the model (confounders).  
To estimate threshold doses, data were analysed using an interval censoring survival analysis 
approach described in the method section. This is considered the best statistical method to 
estimate threshold doses. However, with low numbers, the estimated threshold doses are less 
reliable. In our study, this was the case for the estimated threshold doses for objective 
reactions to salmon and mackerel, reflected by wide confidence intervals for these estimates. 
In TFF2, the study sample was the complete population of adolescents in the geographic area 
of the study. Thus, a formal calculation of power was not regarded as necessary for this study. 
Selection bias due to non-responders are discussed in chapter 4.2.1 (selection bias). 
The primary purpose of the TRO-FAST study, as reported prospectively before study start in 
ClinicalTrials.gov (NCT02365168) was “to determine to which degree fish allergic children 
and adolescents can tolerate some species of fish, and to find the minimal eliciting allergen 
dose to which only 10% of participants get allergic reaction.” We aimed to include 40 
patients. We anticipated that some patients would drop-out due to different reasons, and 
therefore 44 patients were included. Prior to study start, other researchers had reported that up 
to, or more than, 50% of fish allergic patients would be tolerant to some other fish species 
(“partially tolerant”). However, previous studies using “gold standard” investigations with 
DBPCFC were limited and very small. We considered our study sample large enough to 
describe the distribution of partially tolerant and non-tolerant participants. No formal power 
analysis was applied for the sample size, and the sample size was clearly also a pragmatic 
choice based on number of available patients and the very large work-load with both blinded 
and open food challenges on several occasions. However, at least 30 observations is needed to 
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estimate reliable threshold doses for allergic reactions using dose-distributions curves [112]. 
Thus, we expected to have enough power to be able to calculate estimated threshold doses for 
subjective reactions to at least cod. Indeed, we were able to calculate estimated threshold 
doses for subjective reactions to all three fish species, although the difference in age between 
participants may add uncertainty due possible differences in threshold doses in different age 
groups. The estimated threshold doses for objective reactions to salmon and mackerel are less 
reliable and should be interpreted with caution due to less than 30 observations.  
We also investigated secondary outcomes including comparisons of cut-off levels for 
different sIgE’s in the partially tolerant versus the non-tolerant group. Our sample size was 
not powered for these secondary outcomes. We still found significant differences between the 
two groups in several sIgE values indicating that these two groups were different fish allergic 
phenotypes, with different levels of sIgE response. However, we certainly acknowledge that a 
larger sample size would have been an advantage when analysing the sIgE responses. 
However, inclusion of more participants was not possible due restricted number of eligible 
patients and a very costly and time-consuming design of the study. A researcher should 
consider to not perform a study without enough statistical power. Participants may have to go 
through potential harmful procedures without the study being able to answer the study 
questions. However, our sample size was three times larger than the largest study sample 
previously used in a comparable study and we find our sample size to be adequate to answer 
the main purpose of the study. We therefore found it ethical justifiable to perform the study. 
These considerations were also conveyed to the regional ethical committee (REC) in 2013 
prior to study start. We stated clearly that we considered our sample size large enough to find 
and describe the distribution of partially tolerant and non-tolerant participant. Moreover, we 
stated that secondary outcomes would be explored, but that a formal sample size calculation 
could not be based on these secondary outcomes. The study was approved by REC. 
4.3 Ethical considerations 
Ethical issues are relevant in all research on humans and The World Medical Association has 
developed the Declaration of Helsinki as a statement of ethical principles for medical research 
involving human subjects, including research on identifiable human material and data [208].  
Due to the vulnerability of children, research on children has been restricted in many 
countries to protect them from negative effects of research. Researches should be vigilant to 
expose vulnerable subjects to risks and burdens. Traditionally there should be no or very 
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small risk and risks should be justified by a direct benefit to the research subject. A 
consequence of less research is use of non-evidence based treatment to children. It is an 
ethical dilemma that protection from harm due to research, may produce harm due to lack of 
research. This problem has been addressed in the book ”The ethics of paediatric research” 
[209]. In conclusion, the author states that clinical research on children is necessary, even if 
there is a small risk and no benefit for the participant. Bos et al. have explored the legal 
regulation and ethical guidance for paediatric clinical research in the European Union and 
discussed the future challenges in this field [210]. Less research, especially trials with new 
medications, is a consequence of strict regulations for research on children. Therefore, the 
European Union have ordered the pharmaceutical industry to plan trials with children for all 
new medications going into the marked. 
Valid decisions to participate in research must be made voluntarily by legally competent 
adults, after being informed of the nature, significance, implications, risks and burdens of the 
research. Children are not old enough to give legally valid consent and their capacity to 
understand and assess information is limited. As a result, parents are almost always involved 
in decisions to enrol a minor in a clinical trial [210]. This is problematic from an ethical point 
of view, especially if the research involves painful or potentially harmful procedures. 
However, decision-making strategies aim at encouraging shared decision making between the 
parent and the minor research subject. This may include dual consent, consent by the parent 
and agreement of the minor to participate, and respect for the dissent of the child [210]. 
Ondrusek et al concluded that most children younger than 9 years of age cannot be expected 
to consent or assent to clinical research in a meaningful way [211]. 
In TRO-FAST, we recruited children and adolescents. To facilitate shared decision-making 
we adapted separate written information about the study to children, adolescents and parents. 
Under the age of 16, parents’ consent is mandatory. All participants between the age of 12 
and 16 also gave written consent to participate and children between 8 and 12 years of age 
were given the opportunity to sign an agreement to participate. However, in spite of shared 
decision-making, the children could have consented because they felt pressure to do so, either 
from their parents, from the researchers or both. In the study from Ondrusek et al, they 
showed that voluntariness may have been compromised in many subjects by their belief that 
failure to complete the study would displease the parents or the researcher [211]. 
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The Oviedo Convention is binding EU member states and specifically addresses the issue of 
paediatric research in Article 17 [212], supplemented with an additional protocol on 
biomedical research [213]. Important conditions in this article are that the research should 
have potential benefit for the child and should implement minimal risk or burden to the 
research subject. Research on minors should not be done if comparable effectiveness can be 
carried out on individuals capable of giving consent or if the child concerned object to 
participate. 
In TRO-FAST, blood sampling and performing food challenge may have been a burden for 
the participants and the food challenge elicited allergic reactions in many participants. In the 
beginning of the study, some of the youngest children refused to eat the test-food. Some 
parents wanted to persuade the children to continue. This is not in line with the Oviedo 
convention and these children were excluded from the study as dropouts. Still, many 
participants experienced the challenge and the allergic reactions as a burden. However, they 
wanted to continue because they (or their parents) considered it as a benefit to get a specific 
diagnose of their fish allergy in a safe setting. Although the test entails burdens and risk of 
allergic reactions, it is the gold standard in diagnosing food allergy and it is routinely used in 
clinical practice [138]. In spite of risks and burdens, based on these facts, we found it 
ethically justifiable to perform the study among children. Considerations regarding sample 





 Asthma, atopic dermatitis and allergic rhinitis are common chronic diseases among 
adolescents in the Arctic region of Norway. Nearly half of the adolescent population has 
experienced one or more of these diseases by the age of 18-19 and multimorbidity of 
allergic disease exists in 10 % of all adolescents.  
 
 The severity of allergic disease is associated with S. aureus carriage, but its role in the 
pathogenesis and severity is not established. 
 
 Polysensitization to food and inhalant allergens and allergic multimorbidity are associated 
with sensitization to S. aureus enterotoxins. Thus, sensitization to S. aureus enterotoxins 
may play a role in the development of polysensitization to food and inhalant allergens and 
allergic multimorbidity in adolescents. 
 
 Allergy to multiple fish species due to cross-sensitization to multiple fish species are 
common in fish allergic children and adolescents, but among participants challenged with 
three different fish species, half of them had no objective symptoms and around one third 
of them had no subjective symptoms to at least one fish species (partial tolerance).  
 
 Fish allergic patients with partial tolerance should be identified to avoid unnecessary food 
restrictions. Measurement of sIgE against fish allergen extracts and molecules cannot 
substitute oral food challenges, but a combination of clinical history and specific IgE 
measurements may reduce the number of food challenges needed for specific diagnosis of 
fish allergy and tolerance. 
 
 Threshold doses for eliciting allergic reactions seem to be lower for cod, compared to 




6 Future research questions. 
Does S. aureus biofilm production play a role in the development of allergic disease and 
sensitization? If the observed associations between S. aureus carriage/SE-sensitization and 
allergic disease/allergic sensitization represent a causal mechanism, does the ability of S. 
aureus to produce biofilms and create a persistent niche for colonization play a role in this 
mechanism? Analysing S. aureus colonies from the TFF2 cohort with regard to biofilm 
production could contribute to further understanding of the impact of S. aureus on allergic 
disease and sensitization. 
 
Do environmental pollutants play a role in the development of allergic disease and 
sensitization? There has been increasing focus on toxins from environmental pollutants and 
their impact on human health. In TFF2, toxin levels in blood from environmental pollutants 
were measured in all participants. Analysing associations between toxins from environmental 
pollution and allergic disease could contribute to further understanding of risk factors for 
allergic disease. 
 
Can the basophil activation test (BAT) with fish allergens substitute oral food challenges in 
the diagnosis of fish allergy? BAT is a flow cytometry-based assay where the expression of 
activation markers is measured on the surface of basophils following stimulation with 
allergens [139]. Maybe this test (BAT) may have better test properties to identify the 
phenotype of fish allergic patients than skin prick test and serum sIgE? Maybe the use of 
BAT (exposing basophils to fish allergens in a test tube) can further reduce the need for 
exposing the “whole patient” to fish allergens in an OFC? For peanut allergy, BAT can 
discriminate between tolerance and allergy among sensitized individuals and reflect the 
severity and threshold of reaction to peanut [214, 215]. BAT has not been studied with use of 
different fish allergens in diagnosing fish allergy. In a future study, we will compare BAT 
results with the results from DBPCFC. 
Can OFC s improve quality of life in fish allergic children and adolescents? OFC is a 
diagnostic procedure. Can the test also contribute to reduce anxiety related to food allergy and 
thereby contribute to increase quality of life in food allergic children? Many participants and 
parents in TRO-FAST reported that the OFC s made them feel safer and contributed to reduce 
anxiety for allergic reactions, also when they were intolerant. They gained knowledge about 
how they react and how much fish they had to eat before allergic reactions evolved.  With the 
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“Food Allergy Quality of Life Questionnaire” (FAQLQ), this effect on quality of life could be 
measured in a follow-up of the participants.  
 
Does diagnosing tolerance lead to changes in the diet? From clinical experience, we know 
that many patients with previous food allergy do not implement the food in their diet after 
tolerance has been demonstrated with OFC. In a follow-up questionnaire, questions about 
implementation of fish species to which they were tolerant in their diet can answer this 
question. 
 
Can specific oral allergen immunotherapy be used to treat fish allergy? Specific 
immunotherapy for inhalant allergies and insect venom allergies has existed for several 
decades. So far, no safe and efficient immunotherapy is ready for clinical use to treat food 
allergies. Research on food allergy has focused on oral immunotherapy and there is also an 
ongoing project with subcutaneous immunotherapy with fish allergens [83]. An alternative 
route of allergen exposure in specific immunotherapy is transdermal immunotherapy. So far, 
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